subject:(CTLA 4)

University of Rochester

1. Modjeski, Kristina Louise. A Role for Glutamate Receptor Interacting Protein 1 in Platelets and T Cells.

Degree: PhD, 2015, University of Rochester

► PDZ molecular scaffolding proteins have been most studied in neurons, but are present in other cells. PDZ proteins typically bind membrane proteins to regulate receptor… (more)

▼ PDZ molecular scaffolding proteins have been most studied in neurons, but are present in other cells. PDZ proteins typically bind membrane proteins to regulate receptor surface expression and to support junctional complexes. GRIP1 is a 7-PDZ domain scaffolding protein that has roles in neurons to facilitate glutamate receptor trafficking. However, GRIP1 has very different functions in other tissues. GRIP1 is needed to form a junctional barrier between the skin dermis and epidermis. We have found that GRIP1 is expressed in platelets and T cells and that GRIP1 has a functional role in each cell type independent of glutamate receptor signaling. We hypothesized that platelet GRIP1 regulates platelet function and thrombus formation and that T cell GRIP1 regulates T cell activation as evidenced by in vitro studies and using a cardiac transplant model. Platelet-specific GRIP1-/- mice were found to have decreased hemostasis and delayed thrombosis in vivo, but no change in agonist-induced activation in vitro. Using mass spectrometry analysis of proteins that immunoprecipitated with GRIP1, we identified GRIP1 interactions with the GPIb-IX complex. The GPIb-IX complex is necessary for platelet adhesion. We confirmed that GPIb-IX complex protein interactions are different in WT and GRIP1-/- platelets and may cause the in vivo defects. We also investigated GRIP1 function in T cells. WT and T cell-specific GRIP1-/- mice received MHC mismatched cardiac allografts and T cell GRIP1-/- mice had prolonged transplant survival in multiple rejection models. GRIP1-/- T cells had inhibited proliferation and activation following in vitro stimulation. We found that GRIP1-/- T cells had increased surface expression of the strong inhibitory receptor CTLA-4. Blocking CTLA-4 in GRIP1-/- mice rescued transplant rejection. Overall, we have found that GRIP1, a molecular scaffolding protein, has important cell regulatory effects in platelets and T cells that markedly differ in various cell types. We have revealed important functions for GRIP1 in mediating platelet thrombosis and in T cell-mediated transplant rejection.

Subjects/Keywords: Platelets; Adhesion; Transplantation; TCells; CTLA-4

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Modjeski, K. L. (2015). A Role for Glutamate Receptor Interacting Protein 1 in Platelets and T Cells. (Doctoral Dissertation). University of Rochester. Retrieved from http://hdl.handle.net/1802/30116

Chicago Manual of Style (16^th Edition):

Modjeski, Kristina Louise. “A Role for Glutamate Receptor Interacting Protein 1 in Platelets and T Cells.” 2015. Doctoral Dissertation, University of Rochester. Accessed January 17, 2021. http://hdl.handle.net/1802/30116.

MLA Handbook (7^th Edition):

Modjeski, Kristina Louise. “A Role for Glutamate Receptor Interacting Protein 1 in Platelets and T Cells.” 2015. Web. 17 Jan 2021.

Vancouver:

Modjeski KL. A Role for Glutamate Receptor Interacting Protein 1 in Platelets and T Cells. [Internet] [Doctoral dissertation]. University of Rochester; 2015. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/1802/30116.

Council of Science Editors:

Modjeski KL. A Role for Glutamate Receptor Interacting Protein 1 in Platelets and T Cells. [Doctoral Dissertation]. University of Rochester; 2015. Available from: http://hdl.handle.net/1802/30116

Linnaeus University

2. Georgsson, Jonathan. Är CTLA-4-inhibitorn ipilimumab bättre som monoterapi eller i kombination med andra läkemedel hos patienter med metastaserat malignt melanom?.

Degree: Chemistry and Biomedical Sciences, 2016, Linnaeus University

URL: http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-52662

► Malignant melanoma is a growing problem with more and more people in Sweden and the world suffering from this cancer. Malignant melanoma is a… (more)

▼ Malignant melanoma is a growing problem with more and more people in Sweden and the world suffering from this cancer. Malignant melanoma is a disease that when discovered in time can be treated successfully with surgical methods, but the real challenge lies in treating the disease after its spread. Treatment in the past for advanced malignant melanoma has been unsuccessful with no positive effect on overall survival. However, in the last couple of years, new treatment has arrived with focus on priming the immune system to eradicate the tumors. One new drug is the CTLA-4 inhibitor ipilimumab that is given as intravenous infusion. CTLA-4 is a protein located on regulatory T-cells and that is upregulated on activated cytotoxic T-cells. This protein mediates an inhibitory signal that attenuates T-cell-activation. Treatment with the CTLA-4 inhibitor has been shown to increase overall survival. However, not much is known about how well ipilimumab synergizes with other drugs used for treatment of malignant melanoma. This is a literature study with the aim to evaluate if ipilimumab is used best as monotherapy or if it is of better use as part of a combination therapy. Search was made in PubMed with the key-words "Ipilimumab", "Ipilimumab treatment", CTLA-4 inhibitor" and "treatment malignant melanoma”. Six articles were chosen and each of these analyzed the effect of ipilimumab alone or combined with other agents against malignant melanoma. The combination of ipilimumab and the alkylating agent dacarbazine was shown to have a better impact on overall survival compared with monotherapy with dacarbazine, but this combination also showed an increase in serious adverse events. Ipilimumab also showed to work in synergy with both the PD-1-inhibitor nivolumab and the granulocyte macrophage colony-stimulating factor (GM-CSF) sargramostim. Combination with sargramostim was also shown to decrease the amount of serious adverse events. Combination with a gp100 peptide vaccine failed to show any positive effects on overall survival. Also prophylactic treatment with budesonide showed no further gain in overall survival. The effect of ipilimumab was found to have a dose-ranging effect, with higher dose treatment having a better effect but also with more serious adverse events. The results of this literature study showed that ipilimumab has a better effect with higher dose and that it can work in synergy with other agents such as nivolumab and sargramostim. Results also showed that occurring adverse effects during treatment with ipilimumab may be treated with systemic glucocorticoids that did not affect the tumor-killing ability of ipilimumab. These results should be evaluated in bigger studies and with longer follow up time.

Subjects/Keywords: Ipilimumab; CTLA-4; Pharmaceutical Sciences; Farmaceutiska vetenskaper

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Georgsson, J. (2016). Är CTLA-4-inhibitorn ipilimumab bättre som monoterapi eller i kombination med andra läkemedel hos patienter med metastaserat malignt melanom?. (Thesis). Linnaeus University. Retrieved from http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-52662

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Georgsson, Jonathan. “Är CTLA-4-inhibitorn ipilimumab bättre som monoterapi eller i kombination med andra läkemedel hos patienter med metastaserat malignt melanom?.” 2016. Thesis, Linnaeus University. Accessed January 17, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-52662.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Georgsson, Jonathan. “Är CTLA-4-inhibitorn ipilimumab bättre som monoterapi eller i kombination med andra läkemedel hos patienter med metastaserat malignt melanom?.” 2016. Web. 17 Jan 2021.

Vancouver:

Georgsson J. Är CTLA-4-inhibitorn ipilimumab bättre som monoterapi eller i kombination med andra läkemedel hos patienter med metastaserat malignt melanom?. [Internet] [Thesis]. Linnaeus University; 2016. [cited 2021 Jan 17]. Available from: http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-52662.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Georgsson J. Är CTLA-4-inhibitorn ipilimumab bättre som monoterapi eller i kombination med andra läkemedel hos patienter med metastaserat malignt melanom?. [Thesis]. Linnaeus University; 2016. Available from: http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-52662

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Kansas

3. Newton, Amy Nicole. Novel roles for CD23, CTLA-4 and lipoproteins in human T cell function and differentiation.

Degree: PhD, Molecular Biosciences, 2014, University of Kansas

URL: http://hdl.handle.net/1808/19603

► The differentiation of multipotent naïve T cells is influenced by the microenvironment. Cytokines, costimulatory proteins and other biological factors can tune this differentiation process, influencing… (more)

▼ The differentiation of multipotent naïve T cells is influenced by the microenvironment. Cytokines, costimulatory proteins and other biological factors can tune this differentiation process, influencing cell fate. Controlling naïve T cell differentiation can guide the type of immune response elicited since each T cell subset has a specific function in the immune system. In this dissertation, I examine the participation of costimulatory molecules expressed on the surface of naïve CD4+ T cells in differentiation of these cells. I demonstrate that stimulation through the TCR and CTLA-4 directs naïve CD4+ T cell differentiation to regulatory T cells in the absence of exogenous cytokines. I evaluate how combined stimuli influence differentiation and function in T cells. Combined stimulation through CTLA-4 and CD28 (CD3+CD28+CTLA-4) results in distinct functional outcomes from combined stimulation through CTLA-4 and ICAM-1 (CD3+ICAM-1+CTLA-4) or alternatively, ICAM-1 and CD28 (CD3+CD28+ICAM-1). Differentiation to Th1, Th2 or Treg cells has been evaluated in our previous studies. In this dissertation, I extend these studies by examining whether costimulation in the absence of exogenous cytokines can support Th17 differentiation. I found that costimulation through ICAM-1, CD28, LFA-1, or CTLA-4 did not activate naïve CD4+ T cells to differentiate to Th17 cells. I also evaluated how the low affinity IgE receptor, CD23, expressed on T cells participates in naïve T cell differentiation and mature T cell function. CD23 functions as a negative regulator of Th2 responses by inhibiting differentiation of naïve T cells to Th2 cells and enhancing activation of Th1 cells in mature T cells. Next, I examined how lipoproteins relevant to atherosclerosis may guide differentiation of naïve CD4+ T cells. Consistent with their known roles in promoting or inhibiting atherosclerosis, oxLDL activates differentiation to Th1 cells whereas HDL inhibits T cell proliferation and viability. Different responses by naïve T cells to these lipoproteins may have direct implications in how atherosclerosis is exacerbated or attenuated during disease. Finally, I explore whether autoimmunity is involved in a mouse model of emphysema. I demonstrate that T cells adoptively transferred emphysema to naïve, immunodeficient mice, supporting a role for autoimmunity in an elastase-induced model. Peptide therapy targeting the interactions between ICAM-1 and LFA-1 was able to reduce severity of emphysema as well. Advisors/Committee Members: Benedict, Stephen H (advisor), Yankee, Thomas (cmtemember), Egan, Susan (cmtemember), Hefty, Scott (cmtemember), Davido, David (cmtemember).

Subjects/Keywords: Immunology; CTLA-4; differentiation; T cell

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Newton, A. N. (2014). Novel roles for CD23, CTLA-4 and lipoproteins in human T cell function and differentiation. (Doctoral Dissertation). University of Kansas. Retrieved from http://hdl.handle.net/1808/19603

Chicago Manual of Style (16^th Edition):

Newton, Amy Nicole. “Novel roles for CD23, CTLA-4 and lipoproteins in human T cell function and differentiation.” 2014. Doctoral Dissertation, University of Kansas. Accessed January 17, 2021. http://hdl.handle.net/1808/19603.

MLA Handbook (7^th Edition):

Newton, Amy Nicole. “Novel roles for CD23, CTLA-4 and lipoproteins in human T cell function and differentiation.” 2014. Web. 17 Jan 2021.

Vancouver:

Newton AN. Novel roles for CD23, CTLA-4 and lipoproteins in human T cell function and differentiation. [Internet] [Doctoral dissertation]. University of Kansas; 2014. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/1808/19603.

Council of Science Editors:

Newton AN. Novel roles for CD23, CTLA-4 and lipoproteins in human T cell function and differentiation. [Doctoral Dissertation]. University of Kansas; 2014. Available from: http://hdl.handle.net/1808/19603

4. Coutzac, Clélia. Immunomodulation par les anticorps monoclonaux thérapeutiques bloquant CTLA-4 : rôle de la flore intestinale et de ses métabolites : Immunomodulation with CTLA-4 blockade monoclonal antibodies : role of gut microbiota and its metabolites.

Degree: Docteur es, Sciences de la vie et de la santé, 2017, Université Paris-Saclay (ComUE)

URL: http://www.theses.fr/2017SACLS396

►

Au cours des dernières années, l’immunothérapie a révolutionné le paysage en oncologie. L’anti-CTLA-4 a montré son efficacité sur la survie globale des patients atteints de… (more)

▼

Au cours des dernières années, l’immunothérapie a révolutionné le paysage en oncologie. L’anti-CTLA-4 a montré son efficacité sur la survie globale des patients atteints de mélanome métastatique. Cependant, ce traitement présente des limites à son utilisation telles que l'efficacité clinique obtenu chez seulement 20% des patients et la survenue fréquente de colites pouvant être sévères. La recherche de biomarqueurs prédictifs de réponse clinique et/ou de développement de toxicité devient maintenant un enjeu majeur pour sélectionner les patients pouvant avoir un bénéfice à l’utilisation de ces traitements. En partant de l’observation que les colites induites par l’anti-CTLA-4 présentent des similitudes avec les maladies inflammatoires chroniques de l'intestin, nous avons émis l’hypothèse de l’existence d’un microbiote intestinal associé à une dysrégulation du système immunitaire pouvant prédire la réponse clinique et/ou la survenue d’une colite induite par l’anti-CTLA-4. Nous avons montré dans une cohorte de patients atteints de mélanome métastatique et traités par ipilimumab, qu'un microbiote intestinal enrichi en Faecalibacterium et autres Firmicutes est associé à une meilleure survie globale et sans progression ainsi qu'un risque accru de développer une colite. Les patients avec une flore enrichie en Firmicutes présentent également après traitement par ipilimumab, une activation lymphocytaire plus efficace. Par la suite, nous nous sommes intéressés aux métabolites issus du microbiote fécal et leur implication dans la réponse à l'anti-CTLA-4. Le butyrate est le principal métabolite produit par les Firmicutes. Nous avons observé chez la souris, une inhibition de l'efficacité anti-tumorale de l'anti-CTLA-4 lorsqu'elles étaient supplémentées en butyrate. In vivo, nous avons montré que le butyrate inhibe la surexpression sur les cellules dendritiques, des molécules CD80 et CD86 (molécules B7) induite par l'anti-CTLA-4. Cette immaturité des cellules dendritiques entraine un défaut d'activation des lymphocytes T spécifiques d'antigènes dépendant de l'axe CD28/B7 réduisant ainsi l'efficacité anti-tumorale. Chez l'Homme, nous avons valider cette hypothèse en montrant qu'une concentration sérique élevée en butyrate est associée à une diminution de la survie globale et sans progression comparativement aux patients avec un faible niveau de butyrate sérique.Ces travaux mettent en évidence le lien entre la composition du microbiote et les réponses immunologiques au blocage du CTLA-4. Ils apportent une explication sur un lien indirect via le butyrate entre la composition du microbiote intestinal et la réponse anti-tumorale aux immunothérapies.

In the last years, immunotherapy has revolutionized the landscape in oncology. The efficacy of anti-CTLA-4 has been demonstrated by improving overall survival of patients with metastatic melanoma. However, this treatment has limitations to its use such as the clinical efficacy obtained in only 20% of patients and the high incidence of severe colitis. Predictive biomarkers of clinical…

Advisors/Committee Members: Chaput-Gras, Nathalie (thesis director).

Subjects/Keywords: Colite; Ctla-4; Immunothérapie; Cancer; Microbiote intestinal; Butyrate; Colitis; Ctla-4; Immunotherapy; Cancer; Gut Microbiota; Butyrate

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Coutzac, C. (2017). Immunomodulation par les anticorps monoclonaux thérapeutiques bloquant CTLA-4 : rôle de la flore intestinale et de ses métabolites : Immunomodulation with CTLA-4 blockade monoclonal antibodies : role of gut microbiota and its metabolites. (Doctoral Dissertation). Université Paris-Saclay (ComUE). Retrieved from http://www.theses.fr/2017SACLS396

Chicago Manual of Style (16^th Edition):

Coutzac, Clélia. “Immunomodulation par les anticorps monoclonaux thérapeutiques bloquant CTLA-4 : rôle de la flore intestinale et de ses métabolites : Immunomodulation with CTLA-4 blockade monoclonal antibodies : role of gut microbiota and its metabolites.” 2017. Doctoral Dissertation, Université Paris-Saclay (ComUE). Accessed January 17, 2021. http://www.theses.fr/2017SACLS396.

MLA Handbook (7^th Edition):

Coutzac, Clélia. “Immunomodulation par les anticorps monoclonaux thérapeutiques bloquant CTLA-4 : rôle de la flore intestinale et de ses métabolites : Immunomodulation with CTLA-4 blockade monoclonal antibodies : role of gut microbiota and its metabolites.” 2017. Web. 17 Jan 2021.

Vancouver:

Coutzac C. Immunomodulation par les anticorps monoclonaux thérapeutiques bloquant CTLA-4 : rôle de la flore intestinale et de ses métabolites : Immunomodulation with CTLA-4 blockade monoclonal antibodies : role of gut microbiota and its metabolites. [Internet] [Doctoral dissertation]. Université Paris-Saclay (ComUE); 2017. [cited 2021 Jan 17]. Available from: http://www.theses.fr/2017SACLS396.

Council of Science Editors:

Coutzac C. Immunomodulation par les anticorps monoclonaux thérapeutiques bloquant CTLA-4 : rôle de la flore intestinale et de ses métabolites : Immunomodulation with CTLA-4 blockade monoclonal antibodies : role of gut microbiota and its metabolites. [Doctoral Dissertation]. Université Paris-Saclay (ComUE); 2017. Available from: http://www.theses.fr/2017SACLS396

5. 安井, 順一. Minor contribution of cytotoxic T lymphocyte antigen 4 and programmed cell death ligand 1 in immune tolerance against mouse thyrotropin receptor in mice : マウスTSH受容体に対する免疫寛容におけるCTLA-4とPD-L1の寄与は僅かである。.

Degree: 博士(医学), 2015, Nagasaki University / 長崎大学

URL: http://hdl.handle.net/10069/36009

► We have previously shown that wild type (wt) mice exhibit susceptibility to immunization with human (h) thyrotropin receptor (TSHR), but resistance to mouse (m) TSHR,… (more)

Subjects/Keywords: thyrotropin receptor; CTLA-4; PD-L 1; Grave's disease

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

安井, �. (2015). Minor contribution of cytotoxic T lymphocyte antigen 4 and programmed cell death ligand 1 in immune tolerance against mouse thyrotropin receptor in mice : マウスTSH受容体に対する免疫寛容におけるCTLA-4とPD-L1の寄与は僅かである。. (Thesis). Nagasaki University / 長崎大学. Retrieved from http://hdl.handle.net/10069/36009

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

安井, 順一. “Minor contribution of cytotoxic T lymphocyte antigen 4 and programmed cell death ligand 1 in immune tolerance against mouse thyrotropin receptor in mice : マウスTSH受容体に対する免疫寛容におけるCTLA-4とPD-L1の寄与は僅かである。.” 2015. Thesis, Nagasaki University / 長崎大学. Accessed January 17, 2021. http://hdl.handle.net/10069/36009.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

安井, 順一. “Minor contribution of cytotoxic T lymphocyte antigen 4 and programmed cell death ligand 1 in immune tolerance against mouse thyrotropin receptor in mice : マウスTSH受容体に対する免疫寛容におけるCTLA-4とPD-L1の寄与は僅かである。.” 2015. Web. 17 Jan 2021.

Vancouver:

安井 �. Minor contribution of cytotoxic T lymphocyte antigen 4 and programmed cell death ligand 1 in immune tolerance against mouse thyrotropin receptor in mice : マウスTSH受容体に対する免疫寛容におけるCTLA-4とPD-L1の寄与は僅かである。. [Internet] [Thesis]. Nagasaki University / 長崎大学; 2015. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10069/36009.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

安井 �. Minor contribution of cytotoxic T lymphocyte antigen 4 and programmed cell death ligand 1 in immune tolerance against mouse thyrotropin receptor in mice : マウスTSH受容体に対する免疫寛容におけるCTLA-4とPD-L1の寄与は僅かである。. [Thesis]. Nagasaki University / 長崎大学; 2015. Available from: http://hdl.handle.net/10069/36009

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Universidade de Brasília

6. Viviane Furlan Lozano. Análise de polimorfismo no gene CTLA-4 em pacientes com paracoccidioidomicose.

Degree: 2008, Universidade de Brasília

URL: http://bdtd.bce.unb.br/tedesimplificado/tde_busca/arquivo.php?codArquivo=3303

►

A proteína CTLA-4 é expressa principalmente em células T ativadas, possuindo um papel fundamental na resposta imune, exercendo efeito regulador na ativação de célula T… (more)

▼

A proteína CTLA-4 é expressa principalmente em células T ativadas, possuindo um papel fundamental na resposta imune, exercendo efeito regulador na ativação de célula T através da sua ligação com as moléculas da família B7, as quais são expressas em células apresentadoras de antígenos. Polimorfismos do gene CTLA-4 têm sido associados a várias doenças autoimunes e, recentemente, à doenças neoplásicas e infecciosas. A paracoccidioidomicose é uma micose sistêmica, causada pelo fungo dimórfico Paracoccidioides brasiliensis. As manifestações clínicas desta doença estão associadas a vários fatores como a secreção alterada de citocinas, hipergamaglobulinemia, e depressão da imunidade celular, sendo que a hiporesponsividade é também atribuída a uma maior expressão de CTLA-4 em células T de pacientes quando comparados a indivíduos controles. O presente trabalho teve por objetivo estudar a possível associação dos SNPs -318C/T na região promotora e +49A/G do éxon 1 do gene CTLA-4 com a PCM. Para isso, 74 pacientes com PCM e 76 indivíduos controles provenientes de regiões distintas do País tiveram suas freqüências alélicas e genotípicas determinadas. A comparação das freqüências genotípicas e alélicas, entre os grupos pacientes e controles, não mostrou diferenças significativas que pudessem associar o polimorfismo dos SNPs -318 e +49 do gene CTLA-4 com a PCM. A análise dos resultados referentes às freqüências haplotípicas obtidas mostrou que existe um forte desequilíbrio de ligação (D=1) entre os SNPs -318 e +49 para os dois grupos estudados. Porém, a análise realizada não revelou diferenças significativas entre as freqüências haplotípicas dos grupos. Outro ponto importante analisado foi o estudo da estrutura genética (ancestralidade) dos grupos de pacientes e controles. Verificou-se que há predomínio de ancestralidade européia sobre as ancestralidades ameríndia e africana em ambos os grupos. Através desses resultados foi possível determinar que a população utilizada no estudo é geneticamente homogênea, e que o resultado negativo da associação detectado para o gene CTLA-4 e a PCM não está relacionado a ancestralidade da amostragem. Este trabalho demonstra que não foi observada nenhuma associação entre o polimorfismo dos SNPs -318 e +49 do gene CTLA-4 com a resistência e/ou susceptibilidade à Paracoccidioidomicose.

The CTLA-4 protein is mainly expressed in activated T cells and plays an essential role in the immune response through its regulatory effect on T cell activation. This activity is mediated by the binding of CTLA-4 to molecules of the B7 family that are expressed by antigen-presenting cells. Polymorphisms of the CTLA-4 gene have been correlated to several autoimmune pathologies and, more recently, to neoplastic and infectious illnesses. Paracoccidioidomycosis (PCM) is a systemic mycosis caused by the dimorphic pathogen Paracoccidoides brasiliensis. Its symptoms are associated to various factors, including altered secretion of cytokines, hypergammaglobulinaemia and suppression of cellular immunity. This low…

Advisors/Committee Members: Jaime Martins de Santana, Marcelo de Macedo Brigido, Anamélia Lorenzetti Bocca, Maria Sueli Soares Felipe.

Subjects/Keywords: paracoccidioidomicose; ancestralidade; GENETICA; SNP -318; SNP +49; CTLA-4; polimorfismos

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Lozano, V. F. (2008). Análise de polimorfismo no gene CTLA-4 em pacientes com paracoccidioidomicose. (Thesis). Universidade de Brasília. Retrieved from http://bdtd.bce.unb.br/tedesimplificado/tde_busca/arquivo.php?codArquivo=3303

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Lozano, Viviane Furlan. “Análise de polimorfismo no gene CTLA-4 em pacientes com paracoccidioidomicose.” 2008. Thesis, Universidade de Brasília. Accessed January 17, 2021. http://bdtd.bce.unb.br/tedesimplificado/tde_busca/arquivo.php?codArquivo=3303.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Lozano, Viviane Furlan. “Análise de polimorfismo no gene CTLA-4 em pacientes com paracoccidioidomicose.” 2008. Web. 17 Jan 2021.

Vancouver:

Lozano VF. Análise de polimorfismo no gene CTLA-4 em pacientes com paracoccidioidomicose. [Internet] [Thesis]. Universidade de Brasília; 2008. [cited 2021 Jan 17]. Available from: http://bdtd.bce.unb.br/tedesimplificado/tde_busca/arquivo.php?codArquivo=3303.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Lozano VF. Análise de polimorfismo no gene CTLA-4 em pacientes com paracoccidioidomicose. [Thesis]. Universidade de Brasília; 2008. Available from: http://bdtd.bce.unb.br/tedesimplificado/tde_busca/arquivo.php?codArquivo=3303

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Sydney

7. Gide, Tuba Nur. Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma.

Degree: 2019, University of Sydney

URL: http://hdl.handle.net/2123/21200

► Inhibitors targeting the CTLA-4 and PD-1 receptors have greatly improved the survival and outcomes of patients with advanced stage melanoma. There are currently numerous Phase… (more)

▼ Inhibitors targeting the CTLA-4 and PD-1 receptors have greatly improved the survival and outcomes of patients with advanced stage melanoma. There are currently numerous Phase 1-3 clinical trials testing the combination of immune checkpoint inhibitors in metastatic melanoma, including drugs targeting IDO1, LAG3, and TIM3. In order to determine which patients will benefit from a specific therapy, it is vital to first identify predictors of response to immunotherapies. This will allow for the administration of personalised immunotherapies and increase the rate of response for metastatic melanoma patients. While many patients exhibit a response to single-agent or combination immune checkpoint blockade, there exists a subgroup of patients who receive minimal or no benefit from these therapies. These patients often do not respond at all (innate resistance) or relapse after demonstrating an initial response (acquired resistance). For these patients, it is of utmost importance to identify potential mechanisms of resistance and ways in which these signalling molecules or pathways may be targeted in order to elicit an anti-tumour immune response. Therefore, the aim of this thesis is to identify biomarkers of response and mechanisms of resistance to anti-PD-1 monotherapy, or combination anti-PD-1 and anti-CTLA-4 immunotherapy in metastatic melanoma patients. The studies described herein employ various experimental techniques including highly quantitative multiplex immunofluorescence, immunohistochemistry, RNA-sequencing, targeted RNA-sequencing and DNA sequencing on FFPE melanoma specimens, as well as mass cytometry on tumour dissociates. Throughout the studies included in this thesis, I identify potential biomarkers of response to anti-PD-1 based therapies at baseline, including an EOMES+ memory T-cell population associated with significantly longer progression-free survival and tumour shrinkage. I further highlight the application of multiplex immunofluorescence in investigating the spatial distribution of critical immune populations and their potential role as biomarkers of response. Finally, I perform a detailed characterisation of the non-responding patients, and identify pathways associated with resistance to anti-PD-1 based therapies. These findings have significant implications for the treatment and selection of metastatic melanoma patients for anti-PD-1 based therapies.

Subjects/Keywords: melanoma; immunotherapy; anti-PD-1; anti-CTLA-4

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Gide, T. N. (2019). Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma. (Thesis). University of Sydney. Retrieved from http://hdl.handle.net/2123/21200

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Gide, Tuba Nur. “Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma. ” 2019. Thesis, University of Sydney. Accessed January 17, 2021. http://hdl.handle.net/2123/21200.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Gide, Tuba Nur. “Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma. ” 2019. Web. 17 Jan 2021.

Vancouver:

Gide TN. Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma. [Internet] [Thesis]. University of Sydney; 2019. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/2123/21200.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Gide TN. Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma. [Thesis]. University of Sydney; 2019. Available from: http://hdl.handle.net/2123/21200

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

8. Fields, Maria. Homeostasis and function of Regulatory T Cells during Human Immunodeficiency Virus infection.

Degree: PhD, Medicine: Immunology, 2014, University of Cincinnati

URL: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1408709850

► HIV infection remains an important public health problem worldwide, at the end of 2011 UNAIDS estimated that there were 34.0 million people living with HIV… (more)

▼ HIV infection remains an important public health problem worldwide, at the end of 2011 UNAIDS estimated that there were 34.0 million people living with HIV infection. In addition, 2.5 million people were newly infected with HIV, and there were 1.7 million AIDS-related deaths worldwide. HIV causes a gradual loss of immune competence, leading to acquired immunodeficiency syndrome (AIDS). HIV-associated defects in cell-mediated immunity (CMI) are of particular importance, as these impairments lead to a poor control of HIV replication and of other pathogens whose clearance depends on CMI. Notably, a number of immune deficits caused by HIV infection can be partially restored in vitro. In addition, persistent immunological dysfunction is observed in HIV-infected patients under HAART, suggesting the existence of active regulatory mechanisms. Regulatory T cells (Treg) constitute a subset of CD4+ T cells that plays a major role in the homeostasis of the immune system. Compared to healthy individuals, Treg accumulate in the lymphoid tissues and peripheral blood of HIV-infected individuals, even in the absence of detectable viral replication. Treg may be detrimental to the host by substantially decreasing HIV-specific immune responses during HIV infection. However, Treg may also play a beneficial role, by controlling immune activation limiting cellular targets available for HIV infection, as well as decrease the pathology associated with immune activation in HIV. The role of Treg in the setting of acute HIV infection and the mechanisms underlying Treg relative accumulation during HIV infection are still unclear. First, we hypothesize that Treg could decrease acute HIV infection of relevant HIV target cells (CD4+T cells and DC), because of Treg natural ability to decrease T cell activation and DC maturation, which are crucial processes for a successful HIV infection and dissemination. Our results indicate that Treg decreases cell-free and cell-mediated HIV infection of T cells and DC:Tcon cell clusters. Furthermore, there is a clear involvement of CTLA-4 in the Treg-mediated suppression of HIV infection in the DC;Tcon infection model. Importantly, Treg suppresses HIV infection in both models in a cAMP-dependent manner, highlighting the importance of this mechanism in Treg mediated suppression in different systems. Second, set out to determine the molecular factors driving Treg persistence during treated chronic HIV-infection. HAART induces lipid alteration and Treg appear to primarily depend on lipid oxidation for energy generation. We thus hypothesize that lipid changes during HAART contribute to the Treg persistence during treated HIV infection. Increased Treg frequency in treated HIV-infected individuals was positively associated with plasma HDL levels. Treg were more efficient at HDL internalization than naive but not memory CD4+ T cells. Culture of Treg from healthy donors in the presence of HDL promoted their accumulation; whereas HDL did not affect naive and memory T cells. Importantly, the Akt signaling pathway may be… Advisors/Committee Members: Chougnet, Claire (Committee Chair).

Subjects/Keywords: Immunology; Treg; HIV; cAMP; CTLA-4; HDL; Actin

11 more images…

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Fields, M. (2014). Homeostasis and function of Regulatory T Cells during Human Immunodeficiency Virus infection. (Doctoral Dissertation). University of Cincinnati. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1408709850

Chicago Manual of Style (16^th Edition):

Fields, Maria. “Homeostasis and function of Regulatory T Cells during Human Immunodeficiency Virus infection.” 2014. Doctoral Dissertation, University of Cincinnati. Accessed January 17, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1408709850.

MLA Handbook (7^th Edition):

Fields, Maria. “Homeostasis and function of Regulatory T Cells during Human Immunodeficiency Virus infection.” 2014. Web. 17 Jan 2021.

Vancouver:

Fields M. Homeostasis and function of Regulatory T Cells during Human Immunodeficiency Virus infection. [Internet] [Doctoral dissertation]. University of Cincinnati; 2014. [cited 2021 Jan 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1408709850.

Council of Science Editors:

Fields M. Homeostasis and function of Regulatory T Cells during Human Immunodeficiency Virus infection. [Doctoral Dissertation]. University of Cincinnati; 2014. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1408709850

9. Jacquelot, Nicolas. Impact du système immunitaire dans le mélanome métastatique : étude de son rôle pronostique et prédictif. : The Immune System in Metastatic Melanoma : Prognostic and Predictive Roles.

Degree: Docteur es, Sciences de la vie et de la santé, 2016, Université Paris-Saclay (ComUE)

URL: http://www.theses.fr/2016SACLS142

►

Le mélanome métastatique reste un enjeu majeur de santé publique. Les avancées fulgurantes de ces dernières années ont permis d’améliorer la prise en charge thérapeutique,… (more)

▼

Le mélanome métastatique reste un enjeu majeur de santé publique. Les avancées fulgurantes de ces dernières années ont permis d’améliorer la prise en charge thérapeutique, notamment avec l’arrivée des anticorps bloquant ou agonistiques ciblant les molécules de co-inhibition ou de co-stimulation. Cependant, certains patients sont réfractaires à tout traitement. Il est donc nécessaire de mettre en évidence l’importance de certains paramètres immunologiques permettant d’améliorer le suivi des patients de stade III à haut risque de récidive. De plus, il est primordial de découvrir des marqueurs prédictifs associés à la réponse à ces différents traitements immunomodulateurs. Nous avons identifié une association entre une fréquence élevée de CD45RA+CD4+ et de CD3-CD56- au sein des métastases ganglionnaires avec la survenue d’une récidive anticipée.Une forte expression de NKG2D à la surface des lymphocytes T CD8+, une faible proportion de Tregs ou une faible expression de PD-L1 à la surface des T circulants sont associées à une meilleure survie. Aussi, la mise en place d’un test in-vitro étudiant les réactivités fonctionnelles des lymphocytes infiltrant les tumeurs a permis de dégager l’importance de l’expression de CD95/Fas sur les T CD4+ circulants et de CD137/4-1BB sur les T CD8+ circulants dans la prédiction de la réponse à l’ipilimumab (anti-CTLA-4) et à la combinaison ipilimumab + nivolumab (anti-PD-1). Par ailleurs, le pattern d’expression des récepteurs de chimiokines à la surface des lymphocytes T périphériques permet de détecter les localisations métastatiques de mélanome. Cette étude a révélé également l’importance biologique de l’axe CCR9/CCL25 dans l’immunosurveillance naturelle anti-tumorale.

Metastatic melanoma (MM) is an unmet medical need. The development of immune checkpoint blockers (ICB) improved patient’s clinical outcomes. However, some patients still do not respond to these therapies. To adress these issues, we must find some immunological parameters which predict the relapse of high risk resected stage III melanoma patients. Moreover, it is an urgent need to identify some predicting parameters to these ICB. In our studies, high frequencies of CD45RA+CD4+ and CD3-CD56- in metastatic lymph nodes are associated with a short relapse-free survival. Higher expression of NKG2D on CD8 T cells, low Tregs and low PD-L1 expression on circulating T cells are associated with a prolonged overall survival.Furthermore, we designed an in-vitro test to assess intratumor lymphocytes reactivities to ICB and cytokines (IL-2 and IFNα2a). Low expression of CD95/Fas on CD4+ circulating T cells and high expression of CD137/4-1BB on circulating CD8+ T cells are associated with the response to ipilimumab (anti-CTLA-4) and to the combination ipilimumab + nivolumab (anti-PD-1), respectively. In addition, the chemokine receptor pattern expressed at the surface of circulating lymphocytes could predict the metastatic spreading of melanoma. In this last study, we demonstrated the critical role of CCR9/CCL25 pathway in the natural…

Advisors/Committee Members: Zitvogel, Laurence (thesis director).

Subjects/Keywords: Mélanome métastatique; Système immunitaire; Chimiokines; Anti-PD-1; Anti-CTLA-4; Metastatic melanoma; Immune system; Chemokines; Anti-PD-1; Anti-CTLA-4

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Jacquelot, N. (2016). Impact du système immunitaire dans le mélanome métastatique : étude de son rôle pronostique et prédictif. : The Immune System in Metastatic Melanoma : Prognostic and Predictive Roles. (Doctoral Dissertation). Université Paris-Saclay (ComUE). Retrieved from http://www.theses.fr/2016SACLS142

Chicago Manual of Style (16^th Edition):

Jacquelot, Nicolas. “Impact du système immunitaire dans le mélanome métastatique : étude de son rôle pronostique et prédictif. : The Immune System in Metastatic Melanoma : Prognostic and Predictive Roles.” 2016. Doctoral Dissertation, Université Paris-Saclay (ComUE). Accessed January 17, 2021. http://www.theses.fr/2016SACLS142.

MLA Handbook (7^th Edition):

Jacquelot, Nicolas. “Impact du système immunitaire dans le mélanome métastatique : étude de son rôle pronostique et prédictif. : The Immune System in Metastatic Melanoma : Prognostic and Predictive Roles.” 2016. Web. 17 Jan 2021.

Vancouver:

Jacquelot N. Impact du système immunitaire dans le mélanome métastatique : étude de son rôle pronostique et prédictif. : The Immune System in Metastatic Melanoma : Prognostic and Predictive Roles. [Internet] [Doctoral dissertation]. Université Paris-Saclay (ComUE); 2016. [cited 2021 Jan 17]. Available from: http://www.theses.fr/2016SACLS142.

Council of Science Editors:

Jacquelot N. Impact du système immunitaire dans le mélanome métastatique : étude de son rôle pronostique et prédictif. : The Immune System in Metastatic Melanoma : Prognostic and Predictive Roles. [Doctoral Dissertation]. Université Paris-Saclay (ComUE); 2016. Available from: http://www.theses.fr/2016SACLS142

NSYSU

10. Chen, I-ya. Costimulatory molecules as genetic markers for relapse of Gravesâ disease.

Degree: Master, Biological Sciences, 2009, NSYSU

URL: http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0323109-115415

► Gravesâ disease (GD), an organ specific autoimmune disease, requires two signals to activate the T cells. In addition to the specific binding of T cell… (more)

▼ Gravesâ disease (GD), an organ specific autoimmune disease, requires two signals to activate the T cells. In addition to the specific binding of T cell receptor to the antigenic peptide-MHC complex, an antigen-independent costimulatory pathway reportedly require generate subsequent cytokines and cell surface molecules. This regulation of T-cell response is a highly-organized multiple step program. T cell costimulatory signals is found to regulate the magnitude and duration of various type of autoimmune diseases. This study is to test whether genetic polymorphism of these costimulatory genes is related with the disease susceptibility or progression. We anticipated that the candidate genetic makers are beneficial for importing GD management. We recruited 262 GD patients from the Outpatient Department of Endocrine and 200 healthy controls from the Health Screening Center of Chang Gung Memorial Hospital in Kaohsiung.The GD patients were divided into three groups: recurred within 9 months (n=91), between 10-36 months (n=65), and more than 36 months (n=106). Clinical and laboratory attributes included: the genotypes of CTLA-4, CD28, ICOS, PD-1 and CD40; serum levels of T4, T3 and TSH; goiter size and TSH-receptor antibodies at the beginning and end of treatment. Genomic DNA was extracted from peripheral blood leucocytes by kit. The single nuclotide polymorphisms of the candidate genes were genotyped by polymerase chain reaction- restriction fragment length polymorphism and TaqMan® SNP Genotyping Assays with specific primers. Linkage disequilibuium between pairs of polymorphism was estimated by Haploview software. Haplotype analyses were performed using the Hap-Clustering program. Variance and correlation of data was statistically analyzed by Chi-square, general liner model, multiple logistic regression analysis and Kaplan-Meier plot. A p value <0.01 was considered significant. The results showed:(1) Genetic polymorphism within the costimulatory molecules affected the susceptibility and progression of GD; (2) GD patients carried more risk alleles than the controls; (3) Within the GD group, patients harboring more risk alleles wound relapse earlier after drug withdrawal; (4) Number of risk alleles, goiter size and TBII levels at end of treatment were independent predictors of disease relapse; (5) A risk score calculation based on odds ratio of risk alleles correlated with patientsâ relapse time after drug withdrawal. We concluded that patientsâ genetic makers of costimulatory molecules may be helpful in choosing appropriate treatment for GD. Advisors/Committee Members: Pei-Wen Wang (committee member), Feng-Sheng Wang (chair), Ming-Hong Tai (committee member), Ching-Mei Hsu (chair).

Subjects/Keywords: CD40; PDCD-1; ICOS; CTLA-4; CD28; costimulatory factor; Graves' disease; haplotype; single nucleotide polymorphism

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Chen, I. (2009). Costimulatory molecules as genetic markers for relapse of Gravesâ disease. (Thesis). NSYSU. Retrieved from http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0323109-115415

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Chen, I-ya. “Costimulatory molecules as genetic markers for relapse of Gravesâ disease.” 2009. Thesis, NSYSU. Accessed January 17, 2021. http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0323109-115415.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Chen, I-ya. “Costimulatory molecules as genetic markers for relapse of Gravesâ disease.” 2009. Web. 17 Jan 2021.

Vancouver:

Chen I. Costimulatory molecules as genetic markers for relapse of Gravesâ disease. [Internet] [Thesis]. NSYSU; 2009. [cited 2021 Jan 17]. Available from: http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0323109-115415.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Chen I. Costimulatory molecules as genetic markers for relapse of Gravesâ disease. [Thesis]. NSYSU; 2009. Available from: http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0323109-115415

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Washington University in St. Louis

11. Elliott, Jabari Issa. Structural Mechanism of Poxvirus Sabotage of T-cell Costimulation.

Degree: PhD, Biology & Biomedical Sciences (Biochemistry), 2020, Washington University in St. Louis

URL: https://openscholarship.wustl.edu/art_sci_etds/2182

► Poxviruses are characterized by large double stranded DNA genomes that encode numerous proteins tailored for host immune response evasion. Our lab has been investigating a… (more)

Subjects/Keywords: CD28, Cowpox Virus, Cryo-EM, CTLA-4, Immune Evasion, T cell; Biochemistry; Biophysics

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Elliott, J. I. (2020). Structural Mechanism of Poxvirus Sabotage of T-cell Costimulation. (Doctoral Dissertation). Washington University in St. Louis. Retrieved from https://openscholarship.wustl.edu/art_sci_etds/2182

Chicago Manual of Style (16^th Edition):

Elliott, Jabari Issa. “Structural Mechanism of Poxvirus Sabotage of T-cell Costimulation.” 2020. Doctoral Dissertation, Washington University in St. Louis. Accessed January 17, 2021. https://openscholarship.wustl.edu/art_sci_etds/2182.

MLA Handbook (7^th Edition):

Elliott, Jabari Issa. “Structural Mechanism of Poxvirus Sabotage of T-cell Costimulation.” 2020. Web. 17 Jan 2021.

Vancouver:

Elliott JI. Structural Mechanism of Poxvirus Sabotage of T-cell Costimulation. [Internet] [Doctoral dissertation]. Washington University in St. Louis; 2020. [cited 2021 Jan 17]. Available from: https://openscholarship.wustl.edu/art_sci_etds/2182.

Council of Science Editors:

Elliott JI. Structural Mechanism of Poxvirus Sabotage of T-cell Costimulation. [Doctoral Dissertation]. Washington University in St. Louis; 2020. Available from: https://openscholarship.wustl.edu/art_sci_etds/2182

University of Minnesota

12. Zumwalde, Nicholas Alan. The role of ICAM-1 mediated T cell:T cell interactions on CD8+ T cell effector function and differentiation.

Degree: PhD, Microbiology, Immunology and Cancer Biology, 2013, University of Minnesota

URL: http://purl.umn.edu/151553

► CD8+ T cells are vital components to the immune system and serve as crucial effectors in the elimination of infected cells and pathogens. During the… (more)

Subjects/Keywords: CD8+ T cells; CTLA-4; Effector function; ICAM-1; Inhibition; T cell clusters

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Zumwalde, N. A. (2013). The role of ICAM-1 mediated T cell:T cell interactions on CD8+ T cell effector function and differentiation. (Doctoral Dissertation). University of Minnesota. Retrieved from http://purl.umn.edu/151553

Chicago Manual of Style (16^th Edition):

Zumwalde, Nicholas Alan. “The role of ICAM-1 mediated T cell:T cell interactions on CD8+ T cell effector function and differentiation.” 2013. Doctoral Dissertation, University of Minnesota. Accessed January 17, 2021. http://purl.umn.edu/151553.

MLA Handbook (7^th Edition):

Zumwalde, Nicholas Alan. “The role of ICAM-1 mediated T cell:T cell interactions on CD8+ T cell effector function and differentiation.” 2013. Web. 17 Jan 2021.

Vancouver:

Zumwalde NA. The role of ICAM-1 mediated T cell:T cell interactions on CD8+ T cell effector function and differentiation. [Internet] [Doctoral dissertation]. University of Minnesota; 2013. [cited 2021 Jan 17]. Available from: http://purl.umn.edu/151553.

Council of Science Editors:

Zumwalde NA. The role of ICAM-1 mediated T cell:T cell interactions on CD8+ T cell effector function and differentiation. [Doctoral Dissertation]. University of Minnesota; 2013. Available from: http://purl.umn.edu/151553

University of Maryland

13. Cano-Mejia, Juliana. Biodegradable Prussian blue nanoparticles for photothermal immunotherapy of advanced cancers.

Degree: Bioengineering, 2015, University of Maryland

URL: http://hdl.handle.net/1903/17364

► Multifunctional nanoparticles represent a class of materials with diverse therapy and imaging properties that can be exploited for the treatment of cancers that have significantly… (more)

Subjects/Keywords: Biomedical engineering; Nanotechnology; Immunology; anti-CTLA-4; cancer; photothermal immunotherapy; Prussian blue nanoparticles

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Cano-Mejia, J. (2015). Biodegradable Prussian blue nanoparticles for photothermal immunotherapy of advanced cancers. (Thesis). University of Maryland. Retrieved from http://hdl.handle.net/1903/17364

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Cano-Mejia, Juliana. “Biodegradable Prussian blue nanoparticles for photothermal immunotherapy of advanced cancers.” 2015. Thesis, University of Maryland. Accessed January 17, 2021. http://hdl.handle.net/1903/17364.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Cano-Mejia, Juliana. “Biodegradable Prussian blue nanoparticles for photothermal immunotherapy of advanced cancers.” 2015. Web. 17 Jan 2021.

Vancouver:

Cano-Mejia J. Biodegradable Prussian blue nanoparticles for photothermal immunotherapy of advanced cancers. [Internet] [Thesis]. University of Maryland; 2015. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/1903/17364.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Cano-Mejia J. Biodegradable Prussian blue nanoparticles for photothermal immunotherapy of advanced cancers. [Thesis]. University of Maryland; 2015. Available from: http://hdl.handle.net/1903/17364

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

14. Bouros, Spyridon. Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με μελάνωμα υψηλού κινδύνου για υποτροπή, που λαμβάνουν θεραπεία με ιντερφερόνη και συσχέτισή τους με την πρόγνωση.

Degree: 2014, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)

URL: http://hdl.handle.net/10442/hedi/41686

►

Purpose: Interferon is approved for adjuvant treatment of patients with stage IIb/III melanoma. The toxicity and uncertainty regarding survival benefits of interferon have qualified its… (more)

▼

Purpose: Interferon is approved for adjuvant treatment of patients with stage IIb/III melanoma. The toxicity and uncertainty regarding survival benefits of interferon have qualified its acceptance, despite significant durable relapse prevention in a fraction of patients. Predictive biomarkers that would enable selection of patients for therapy would have a large impact upon clinical practice. Specific CTLA-4 polymorphisms have previously shown an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of autoimmunity.Experimental design: 286 melanoma patients and 288 healthy controls were genotyped for six CTLA-4 polymorphisms previously suggested to be important (AG 49, CT 318, CT 60, JO 27, JO30 and JO 31). Specific allele frequencies were compared between the healthy and patient populations, as well as presence or absence of these in relation to recurrence. Alleles related to autoimmune disease were also investigated.Results: No significant differences were found between the distributions of CTLA-4 polymorphisms in the melanoma population compared with healthy controls. Relapse free survival (RFS) and overall survival (OS) did not differ significantly between patients with the alleles represented by these polymorphisms. No correlation between autoimmunity and specific alleles was shown. The six polymorphisms evaluated where strongly associated (Fisher’s exact p-values<0.001 for all associations) and significant linkage disequilibrium among these was indicated.Conclusion: No polymorphisms of CTLA-4 defined by the SNPs studied were correlated with improved RFS, OS, or autoimmunity in this high-risk group of melanoma patients.

Σκοπός: Η ιντερφερόνη θεωρείται καθιερωμένη επικουρική θεραπεία σε ασθενείς με κακόηθες μελάνωμα σταδίων ΙΙΒ, ΙΙC και ΙΙΙ. Είναι όμως περιορισμένης αποδοχής λόγω της τοξικότητας και της αβεβαιότητας όσον αφορά το όφελος της επιβίωσης, καίτοι βελτιώνει σημαντικά την ελεύθερη υποτροπής επιβίωση σε μία υποομάδα ασθενών με κακόηθες μελάνωμα. Επομένως, θα ήταν χρήσιμο να κατανοήσουμε καλύτερα τους μηχανισμούς δράσης της ιντερφερόνης άλφα-2b και να αναγνωρίσουμε προγνωστικούς δείκτες που θα μας επιτρέψουν να ξεχωρίσουμε τους ασθενείς που είναι πιθανότερο να ωφεληθούν από τη θεραπεία με IFN-a2b. Ο σκοπός αυτής της μελέτης είναι η αναζήτηση 6 πολυμορφισμών του CTLA-4 και η εκτίμηση της επίδρασης της έκφρασής τους στην επιβίωση ασθενών με μελάνωμα υψηλού κινδύνου οι οποίοι λαμβάνουν επικουρική θεραπεία με ιντερφερόνη υψηλής δόσης (HDI). Μεθοδολογία και ασθενείς: Στη μελέτη περιλήφθηκαν διακόσιοι ογδόντα τέσσερις (284) ασθενείς με μελάνωμα σταδίου ΙΙΒ, ΙΙC και ΙΙΙ και 288 υγιείς μάρτυρες. Περιφερικό αίμα ελήφθη πριν από την έναρξη της επικουρικής ανοσοθεραπείας με ιντερφερόνη. Το DNA απομονώθηκε χρησιμοποιώντας το σύστημα εξαγωγής GenoPrep και για την ανίχνευση των πολυμορφισμών (SNP-PCR) του CTLA-4 (AG 49, CT 60, CT 318, JO 27, JO 30, JO 31 και του HLA-Cw*06) χρησιμοποιήθηκε η αλυσιδωτή αντίδραση της πολυμεράσης. Όλες οι αντιδράσεις ανάγνωσης αλληλουχίας…

Subjects/Keywords: Μελάνωμα; Προγνωστικός παράγοντας; Μαθηματικό μοντέλο; Ιντερφερόνη; Melanoma; Interferon; CTLA-4; Prognostic factors; Mathematical model

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Bouros, S. (2014). Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με μελάνωμα υψηλού κινδύνου για υποτροπή, που λαμβάνουν θεραπεία με ιντερφερόνη και συσχέτισή τους με την πρόγνωση. (Thesis). National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Retrieved from http://hdl.handle.net/10442/hedi/41686

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Bouros, Spyridon. “Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με μελάνωμα υψηλού κινδύνου για υποτροπή, που λαμβάνουν θεραπεία με ιντερφερόνη και συσχέτισή τους με την πρόγνωση.” 2014. Thesis, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Accessed January 17, 2021. http://hdl.handle.net/10442/hedi/41686.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Bouros, Spyridon. “Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με μελάνωμα υψηλού κινδύνου για υποτροπή, που λαμβάνουν θεραπεία με ιντερφερόνη και συσχέτισή τους με την πρόγνωση.” 2014. Web. 17 Jan 2021.

Vancouver:

Bouros S. Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με μελάνωμα υψηλού κινδύνου για υποτροπή, που λαμβάνουν θεραπεία με ιντερφερόνη και συσχέτισή τους με την πρόγνωση. [Internet] [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2014. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10442/hedi/41686.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Bouros S. Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με μελάνωμα υψηλού κινδύνου για υποτροπή, που λαμβάνουν θεραπεία με ιντερφερόνη και συσχέτισή τους με την πρόγνωση. [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2014. Available from: http://hdl.handle.net/10442/hedi/41686

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

15. 심, 지현. Altered Expression of Costimulatory Molecules in Behcet's Disease According to Clinical Activity.

Degree: 2010, Ajou University

URL: http://repository.ajou.ac.kr/handle/201003/1321 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000010486

► BACKGROUND: Behcet's Disease disease (BD) is a multisystemic inflammatory disorder. Several reports have suggested that autoimmunity, more precisely, failure to control autoreactive immune cells in… (more)

▼ BACKGROUND: Behcet's Disease disease (BD) is a multisystemic inflammatory disorder. Several reports have suggested that autoimmunity, more precisely, failure to control autoreactive immune cells in the periphery may play a crucial role in BD. To produce a balanced immune response, key inhibitory costimulartory molecules that critically affect peripheral T cell tolerance and T cell function includes the cytotoxic T-lymphocyte antigen-4 (CTLA-4)/CD80, CD86 and programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) receptor/ligand systems are important. Also, regulatory T (Treg) cells play an important role in maintaining immune homeostasis. PURPOSE: The objective of the present study was to determine the immunopathological implication of costimulatory molecules in BD. I investigated cell surface expression of CTLA-4 and PD-1 on T cells and Treg cells, as well as cell surface expression of CD80, CD86, PD-L1 on antigen presenting cells (APCs). Also, I measured the concentration of soluble CTLA-4 (sCTLA-4) from serum and culture supernatants. MATERIALS AND METHODS: From January 2009 to June 2009, a total of 19 patients with BD were enrolled in this study. The disease control and healthy control (HC) group consisted of age- and sex-matched 8 recurrent aphthous ulcer (RAU) patients without any other evident disease and 10 healthy volunteers, respectively. PBMCs of subjects were cultured and stained with the appropriate fluorescent antibody for analysis by flow cytometry. To measure the sCTLA-4 concentrations in serum and in culture supernatants, ELISA was performed. To investigate the mRNA expression level of sCTLA-4 and PD-L1 in PBMCs, real time PCR was performed. RESULTS: In active BD group, the surface expression of CTLA-4 on CD4+ T cells was decreased in the stimulated state compared with HC group. In contrast, the surface expression of PD-1 on CD4+ T cells and CTLA-4 on CD8+ T cells did not show significant differences among each group. There were no differences of CD80 expression on APCs among each group, however, the surface expression of CD86 on APCs was impaired in active BD group compared with HC and inactive BD group in unstimulated state. Also, the surface expression of PD-L1 on APCs was decreased in active BD group compared with other group in unstimulated state. In addition, the surface expression of PD-L1 on APCs was decreased not only in active BD group, but also in inactive BD group at 48 hours after stimulation compared with other group. Proportion of CD4+CD25+highFOXP3+ T cells on CD4+ T cells was decreased in active BD group compared with inactive BD group. Significantly decreased percentage of CTLA-4 expressing CD4+CD25+high T cells was observed in active BD group compared with HC group in stimulated state, but surface PD-1 expression on CD4+CD25+high T cells did not show any differences among each group. Abnormal high serum concentration of sCTLA-4 was appeared in active BD group compared with HC group and RAU group. However, after stimulation, significant differences of sCTLA-4 concentration were… Advisors/Committee Members: 대학원 의학과, 200824366, 심, 지현.

Subjects/Keywords: Behcet's Disease; CTLA-4; sCTLA-4; PD-L1

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

심, �. (2010). Altered Expression of Costimulatory Molecules in Behcet's Disease According to Clinical Activity. (Thesis). Ajou University. Retrieved from http://repository.ajou.ac.kr/handle/201003/1321 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000010486

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

심, 지현. “Altered Expression of Costimulatory Molecules in Behcet's Disease According to Clinical Activity.” 2010. Thesis, Ajou University. Accessed January 17, 2021. http://repository.ajou.ac.kr/handle/201003/1321 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000010486.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

심, 지현. “Altered Expression of Costimulatory Molecules in Behcet's Disease According to Clinical Activity.” 2010. Web. 17 Jan 2021.

Vancouver:

심 �. Altered Expression of Costimulatory Molecules in Behcet's Disease According to Clinical Activity. [Internet] [Thesis]. Ajou University; 2010. [cited 2021 Jan 17]. Available from: http://repository.ajou.ac.kr/handle/201003/1321 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000010486.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

심 �. Altered Expression of Costimulatory Molecules in Behcet's Disease According to Clinical Activity. [Thesis]. Ajou University; 2010. Available from: http://repository.ajou.ac.kr/handle/201003/1321 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000010486

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

16. Vinot, Pierre-Axel. Développement de pseudo-particules rétrovirales comme vaccin tolérogène et application dans l'allergie alimentaire : Retrovirus derived Virus-like particles as tolerogenic vaccines for food allergy treatment.

Degree: Docteur es, Immunologie, 2018, Sorbonne université

URL: http://www.theses.fr/2018SORUS268

►

L’incidence croissante des désordres immunitaires a motivé le développement de nouvelles approches permettant l’induction d’une tolérance immunitaire spécifique et maintenue dans le temps. S’inscrivant dans… (more)

▼

L’incidence croissante des désordres immunitaires a motivé le développement de nouvelles approches permettant l’induction d’une tolérance immunitaire spécifique et maintenue dans le temps. S’inscrivant dans ce cadre, la vaccination tolérogène exploite les propriétés innées du système immunitaire pour rétablir la tolérance en visant spécifiquement les cellules dendritiques et les lymphocytes T régulateurs. Ce concept se confronte néanmoins à certaines limitations dues au besoin d’apporter l’antigène sous une forme particulière ou de manière combinée avec un signal de tolérance. En exploitant les propriétés natives des pseudo-particules dérivées de rétrovirus, nous avons mis au point une plateforme permettant de répondre à ces problématiques propres à la vaccination tolérogène. Par ce travail de thèse, l’objectif fut de démontrer la faisabilité de cette approche, en produisant et caractérisant des VLP exprimant l’ovalbumine au sein de la capside et présentant le CTLA-4 à leur surface. Par une étude fonctionnelle sur les cellules dendritiques et sur des cellules présentant une spécificité réactionnelle pour l’ovalbumine, nous avons démontré les propriétés tolérogènes de ces VLP. Ces propriétés ont par la suite été confirmées dans un modèle d’allergie alimentaire induite à l’ovalbumine chez la souris. Les résultats obtenus montrent pour la première fois que ces VLP tolérogènes permettent le contrôle de l’allergie alimentaire de manière spécifique et à long terme et fournissent la preuve de concept de leur utilisation. Les travaux entrepris permettent d’envisager l’utilisation de ces particules dans d’autres champs d’application et notamment les maladies auto-immunes.

The increasing incidence of immune disorders has motivated the development of innovative approaches allowing the induction of a specific and long-lasting immune tolerance. Tolerogenic vaccination stands as one of those new therapies and exploits the innate properties of the immune system to restore tolerance by specifically targeting major players such as dendritic cells and regulatory T cells. Nevertheless, this concept faces certain limitations due to the need to provide the antigen in a particular form or in combination with a tolerance signal. By exploiting the native properties of pseudo-particles derived from retroviruses, we have developed a platform to answer those needs. With this thesis research, the objective was to highlight the feasibility of this approach by producing and characterizing VLPs expressing ovalbumin within the capsid and presenting CTLA-4 molecules on their surface. By functional studies on dendritic cells and on ovalbumin specific T cells, we highlight the tolerogenic properties of these VLPs. These properties were subsequently confirmed in a model of ovalbumin-induced food allergy in mice. The obtained results demonstrate for the first time that these tolerogenic VLPs allow the control of food allergy in a specific and long-lasting manner, thus supporting the proof of concept of their use. Additional work also makes it…

Advisors/Committee Members: Bellier, Bertrand (thesis director).

Subjects/Keywords: Immunologie; Immunothérapie; Tolérance; Pseudo-particules rétrovirales; Allergie; CTLA-4; Immunology; Immunotherapy; Virus-like particles; Allergy; 571.963

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Vinot, P. (2018). Développement de pseudo-particules rétrovirales comme vaccin tolérogène et application dans l'allergie alimentaire : Retrovirus derived Virus-like particles as tolerogenic vaccines for food allergy treatment. (Doctoral Dissertation). Sorbonne université. Retrieved from http://www.theses.fr/2018SORUS268

Chicago Manual of Style (16^th Edition):

Vinot, Pierre-Axel. “Développement de pseudo-particules rétrovirales comme vaccin tolérogène et application dans l'allergie alimentaire : Retrovirus derived Virus-like particles as tolerogenic vaccines for food allergy treatment.” 2018. Doctoral Dissertation, Sorbonne université. Accessed January 17, 2021. http://www.theses.fr/2018SORUS268.

MLA Handbook (7^th Edition):

Vinot, Pierre-Axel. “Développement de pseudo-particules rétrovirales comme vaccin tolérogène et application dans l'allergie alimentaire : Retrovirus derived Virus-like particles as tolerogenic vaccines for food allergy treatment.” 2018. Web. 17 Jan 2021.

Vancouver:

Vinot P. Développement de pseudo-particules rétrovirales comme vaccin tolérogène et application dans l'allergie alimentaire : Retrovirus derived Virus-like particles as tolerogenic vaccines for food allergy treatment. [Internet] [Doctoral dissertation]. Sorbonne université; 2018. [cited 2021 Jan 17]. Available from: http://www.theses.fr/2018SORUS268.

Council of Science Editors:

Vinot P. Développement de pseudo-particules rétrovirales comme vaccin tolérogène et application dans l'allergie alimentaire : Retrovirus derived Virus-like particles as tolerogenic vaccines for food allergy treatment. [Doctoral Dissertation]. Sorbonne université; 2018. Available from: http://www.theses.fr/2018SORUS268

Universitat de Girona

17. Bosch Vizcaya, Anna. Antígens menors d'histocompatibilitat en el trasplantament al·logènic de progenitors hematopoètics. Modulació de la resposta en funció del genotip CTLA-4.

Degree: Departament de Ciències Mèdiques, 2016, Universitat de Girona

URL: http://hdl.handle.net/10803/398011

► Els antígens menors d’histocompatibilitat (AgsmH) són pèptids precedents de proteïnes polimòrfiques endògenes que poden ser reconegudes en un context al·logènic pels limfòcits T del donant,… (more)

Subjects/Keywords: Antígens menors d'histocompatibilitat; Antígenos menores de histocompatibilidad; Minor histocompatibility antigens; Trasplantament al·logènic; Trasplante alogénico; Allogeneic transplantation; CTLA-4; 576; 61

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Bosch Vizcaya, A. (2016). Antígens menors d'histocompatibilitat en el trasplantament al·logènic de progenitors hematopoètics. Modulació de la resposta en funció del genotip CTLA-4. (Thesis). Universitat de Girona. Retrieved from http://hdl.handle.net/10803/398011

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Bosch Vizcaya, Anna. “Antígens menors d'histocompatibilitat en el trasplantament al·logènic de progenitors hematopoètics. Modulació de la resposta en funció del genotip CTLA-4.” 2016. Thesis, Universitat de Girona. Accessed January 17, 2021. http://hdl.handle.net/10803/398011.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Bosch Vizcaya, Anna. “Antígens menors d'histocompatibilitat en el trasplantament al·logènic de progenitors hematopoètics. Modulació de la resposta en funció del genotip CTLA-4.” 2016. Web. 17 Jan 2021.

Vancouver:

Bosch Vizcaya A. Antígens menors d'histocompatibilitat en el trasplantament al·logènic de progenitors hematopoètics. Modulació de la resposta en funció del genotip CTLA-4. [Internet] [Thesis]. Universitat de Girona; 2016. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10803/398011.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Bosch Vizcaya A. Antígens menors d'histocompatibilitat en el trasplantament al·logènic de progenitors hematopoètics. Modulació de la resposta en funció del genotip CTLA-4. [Thesis]. Universitat de Girona; 2016. Available from: http://hdl.handle.net/10803/398011

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

18. Deshpande, Janhavee. Cell-mediated immunotherapy: its role in cancer treatment.

Degree: MS, Medical Sciences, 2017, Boston University

URL: http://hdl.handle.net/2144/23796

► Cancer is the second most common cause of death in the United States behind heart disease. While current treatments such as surgery, chemotherapy, and radiation… (more)

▼ Cancer is the second most common cause of death in the United States behind heart disease. While current treatments such as surgery, chemotherapy, and radiation therapy are effective and widely used, medicine is moving towards more targeted and personalized therapies. Immunotherapy is one such treatment that utilizes the patient’s own immune system to target and eliminate tumor cells. It allows for the patient’s adaptive immune system to bypass the self-tolerance mechanisms used by the cancerous cells and be activated against the cancer. Two such self-tolerant mechanisms that are co-opted by tumor cells are the interactions between CTLA-4 and T lymphocytes and the interactions between PD-1 and PD-L1. Blocking these interactions allows for the recruitment of CTLs to the site of the tumor and subsequent attack. CTLA-4 and PD-1 are inhibitory costimulators that play a role in the suppression of the adaptive immune system. The interaction of these receptors with their respective ligands leads to self-tolerance, and is a common mechanism used as a protective measure against autoimmune reactions. Monoclonal antibodies against these two receptors and ligand have been tested in clinical trials and have shown efficacy against ovarian cancers, non-small cell lung carcinomas, colon cancers, and melanomas. By targeting the inhibitory signals, these monoclonal antibodies expose cancer cells as being “non-self” thus prompting the immune system to attack. Now, studies are focusing on combination therapies, which combine chemotherapeutics or other monoclonal antibodies with PD-1 and CTLA-4 inhibitors to enhance the effectiveness of the drug. However, drawbacks and side effects to the therapy range from fatigue and nausea to development of autoimmune diseases. It brings forward that future studies will need a panel of predictive biomarkers to identify the best candidates for the immunotherapy. While there are many obstacles, such as a lower than expected efficacy of the immunotherapy, the progress made has important implications in the development of personalized medicine.

Subjects/Keywords: Immunology; CTLA-4; PD-1; Immunotherapy

…results of anti-CTLA-4 mAb on advanced 48 melanoma patients. 12 The CTLA-4, PD-1, and PD-L1… …FIGURES Figure 1 Title The blockade of PD-1 and CTLA-4 signaling in tumor Page 3… …Carcinoembryonic antigen CTL �� …..Cytotoxic T Lymphocytes CTLA-4… …CTLA-4) receptors and programmed death 1 receptor and its ligand (PD-1, PD-L1)… …T lymphocytes recognize CTLA-4 and PD-1 on cancer cells, which allows the cancer cells to…

11 more images…

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Deshpande, J. (2017). Cell-mediated immunotherapy: its role in cancer treatment. (Masters Thesis). Boston University. Retrieved from http://hdl.handle.net/2144/23796

Chicago Manual of Style (16^th Edition):

Deshpande, Janhavee. “Cell-mediated immunotherapy: its role in cancer treatment.” 2017. Masters Thesis, Boston University. Accessed January 17, 2021. http://hdl.handle.net/2144/23796.

MLA Handbook (7^th Edition):

Deshpande, Janhavee. “Cell-mediated immunotherapy: its role in cancer treatment.” 2017. Web. 17 Jan 2021.

Vancouver:

Deshpande J. Cell-mediated immunotherapy: its role in cancer treatment. [Internet] [Masters thesis]. Boston University; 2017. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/2144/23796.

Council of Science Editors:

Deshpande J. Cell-mediated immunotherapy: its role in cancer treatment. [Masters Thesis]. Boston University; 2017. Available from: http://hdl.handle.net/2144/23796

Arizona State University

19. Lussier, Danielle Marie. Increasing T Cell Immunity to Metastatic Osteosarcoma via Modulation of Inhibitory T Cell Receptors.

Degree: Molecular and Cellular Biology, 2015, Arizona State University

URL: http://repository.asu.edu/items/29627

► Osteosarcoma is the most common bone cancer in children and adolescents. Patients with metastatic osteosarcoma are typically refractory to treatment. Numerous lines of evidence suggest… (more)

Subjects/Keywords: Immunology; Molecular biology; Cellular biology; CTLA-4; Inhibitory Receptors; Metastatic Osteosarcoma; PD-1; PD-L1; T cell exhaustion

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Lussier, D. M. (2015). Increasing T Cell Immunity to Metastatic Osteosarcoma via Modulation of Inhibitory T Cell Receptors. (Doctoral Dissertation). Arizona State University. Retrieved from http://repository.asu.edu/items/29627

Chicago Manual of Style (16^th Edition):

Lussier, Danielle Marie. “Increasing T Cell Immunity to Metastatic Osteosarcoma via Modulation of Inhibitory T Cell Receptors.” 2015. Doctoral Dissertation, Arizona State University. Accessed January 17, 2021. http://repository.asu.edu/items/29627.

MLA Handbook (7^th Edition):

Lussier, Danielle Marie. “Increasing T Cell Immunity to Metastatic Osteosarcoma via Modulation of Inhibitory T Cell Receptors.” 2015. Web. 17 Jan 2021.

Vancouver:

Lussier DM. Increasing T Cell Immunity to Metastatic Osteosarcoma via Modulation of Inhibitory T Cell Receptors. [Internet] [Doctoral dissertation]. Arizona State University; 2015. [cited 2021 Jan 17]. Available from: http://repository.asu.edu/items/29627.

Council of Science Editors:

Lussier DM. Increasing T Cell Immunity to Metastatic Osteosarcoma via Modulation of Inhibitory T Cell Receptors. [Doctoral Dissertation]. Arizona State University; 2015. Available from: http://repository.asu.edu/items/29627

20. Marabelle, Aurélien. Targeting Tumor Specific Regulatory T-cells for Cancer Therapy : Traitement du Cancer par Ciblage des Lymphocytes T-régulateurs Spécifiques des Antigènes Tumoraux.

Degree: Docteur es, Sciences de la Vie, 2013, Lyon, École normale supérieure

URL: http://www.theses.fr/2013ENSL0832

►

L'activation de TLR9 par injection directe de nucléotides CpG non méthylés dans une tumeur peut induire une réponse immunitaire thérapeutique, mais les lymphocytes T régulateurs… (more)

▼

L'activation de TLR9 par injection directe de nucléotides CpG non méthylés dans une tumeur peut induire une réponse immunitaire thérapeutique, mais les lymphocytes T régulateurs (Tregs) inhibent ensuite la réponse immunitaire antitumorale et limitent ainsi le pouvoir des stratégies d'immunothérapies contre le cancer.Chez des souris porteuses de tumeurs, nous avons constaté que les Tregs dans la tumeur expriment préférentiellement les marqueurs cellulaires de surface CTLA-4 et OX40. Nous montrons que la co-injection intratumorale d'anti-CTLA-4 et anti-OX40 avec du CpG en intra-tumoral aboutit à l’élimination des Tregs infiltrant la tumeur. Cette immunomodulation in situ, réalisée avec de faibles doses d'anticorps dans une tumeur unique, génère une réponse immunitaire antitumorale systémique capable d’éradiquer la maladie disséminée chez la souris. De plus, cette modalité de traitement est efficace contre des lésions de lymphome du SNC avec métastases leptoméningées, des sites qui sont généralement considérés comme des sanctuaires de cellules tumorales pour les traitements systémiques conventionnels.Ces résultats démontrent que les effecteurs immunitaires anti-tumoraux activés par immunomodulation locale peuventt éradiquer des cellules tumorales siègeant dans des sites éloignés. Nous proposons que, plutôt que d'utiliser des anticorps monoclonaux pour cibler les cellules cancéreuses par voie systémique, des anticorps monoclonaux pourraient être utilisés pour cibler les cellules immunitaires infiltrant la tumeur localement, provoquant ainsi une réponse immunitaire systémique.

Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, regulatory T-cells (Tregs) eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti–CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.

Advisors/Committee Members: Caux, Christophe (thesis director).

Subjects/Keywords: Cancer; Immunothérapies; Lymphocytes T-régulateurs; Anticorps immunomodulateurs; CTLA-4; OX40; CpG; Toll-Like Receptor 9; Cancer; Immunotherapies; Regulatory T-cells; Checkpoint blockade antibodies; CTLA-4; OX40; CpG; Toll-Like Receptor 9

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Marabelle, A. (2013). Targeting Tumor Specific Regulatory T-cells for Cancer Therapy : Traitement du Cancer par Ciblage des Lymphocytes T-régulateurs Spécifiques des Antigènes Tumoraux. (Doctoral Dissertation). Lyon, École normale supérieure. Retrieved from http://www.theses.fr/2013ENSL0832

Chicago Manual of Style (16^th Edition):

Marabelle, Aurélien. “Targeting Tumor Specific Regulatory T-cells for Cancer Therapy : Traitement du Cancer par Ciblage des Lymphocytes T-régulateurs Spécifiques des Antigènes Tumoraux.” 2013. Doctoral Dissertation, Lyon, École normale supérieure. Accessed January 17, 2021. http://www.theses.fr/2013ENSL0832.

MLA Handbook (7^th Edition):

Marabelle, Aurélien. “Targeting Tumor Specific Regulatory T-cells for Cancer Therapy : Traitement du Cancer par Ciblage des Lymphocytes T-régulateurs Spécifiques des Antigènes Tumoraux.” 2013. Web. 17 Jan 2021.

Vancouver:

Marabelle A. Targeting Tumor Specific Regulatory T-cells for Cancer Therapy : Traitement du Cancer par Ciblage des Lymphocytes T-régulateurs Spécifiques des Antigènes Tumoraux. [Internet] [Doctoral dissertation]. Lyon, École normale supérieure; 2013. [cited 2021 Jan 17]. Available from: http://www.theses.fr/2013ENSL0832.

Council of Science Editors:

Marabelle A. Targeting Tumor Specific Regulatory T-cells for Cancer Therapy : Traitement du Cancer par Ciblage des Lymphocytes T-régulateurs Spécifiques des Antigènes Tumoraux. [Doctoral Dissertation]. Lyon, École normale supérieure; 2013. Available from: http://www.theses.fr/2013ENSL0832

21. Dupaty, Léa. Evaluation in vivo de protéines immunorégulatrices dérivées de CTLA-4 et de PD-L1 pour leur capacité à inhiber les réponses immunitaires dans le contexte de la thérapie génique musculaire par AAV : In-vivo evaluation of immunoregulatory proteins derived from CTLA-4 and PD-L1 for their capacity to inhibit immuno responses in a context of AAV muscle gene therapy.

Degree: Docteur es, Sciences de la vie et de la sante, 2018, Normandie

URL: http://www.theses.fr/2018NORMR133

►

La thérapie génique consiste à introduire du matériel génétique dans des cellules dans l’objectif de traiter une pathologie. Le plus souvent, la thérapie génique s’effectue… (more)

▼

La thérapie génique consiste à introduire du matériel génétique dans des cellules dans l’objectif de traiter une pathologie. Le plus souvent, la thérapie génique s’effectue au moyen d’un vecteur viral, transportant le gène jusque dans les cellules cibles. Dans le cas des maladies monogéniques, l’adeno-associated virus (AAV) s’est imposé progressivement comme un vecteur de choix. Son absence de pathogénicité, son large tropisme et sa capacité à transduire des cellules quiescentes sont autant d’avantages comparés à d’autres vecteurs utilisés en thérapie génique. L’utilisation d’AAV est approuvé en Europe pour le traitement d’un déficit rare en lipoprotéine lipase et vient récemment d’être approuvé par les autorités américaines pour le traitement d’un déficit de la vision. Toutefois, les essais de thérapies géniques se heurtent souvent aux réponses immunitaires dirigées contre l’AAV. En effet, les différents composants de ce vecteur viral ont été identifiés comme pouvant déclencher des réponses immunitaires s’opposant à l’efficacité à long terme de la thérapie génique. De plus, la protéine transgénique peut s’avérer immunogène, ce qui conduit au déclenchement de réponses immunitaires, à la destruction des cellules transduites et in fine à l’échec de la thérapie génique. En clinique, des immunosuppresseurs sont utilisés pour palier à ses effets indésirables. Toutefois, de par leurs effets secondaires infectieux et tumorigènes, des stratégies visant plutôt à induire de la tolérance vis-à-vis de la protéine transgénique, associées à un bénéfice pour la santé des patients, se sont développées.L’objectif de ce travail de thèse a été d’implémenter une nouvelle stratégie visant à étudier l’effet immunorégulateur et tolérogène de protéines de fusion dérivées de CTLA-4/Fc et de PD-L1/Fc. Pour cela, nous avons utilisé un modèle murin récapitulant les réponses immunitaires induites par un AAV permettant l’expression d’une protéine modèle fortement immunogène, l’ovalbumine (Ova). Ensuite, des AAV codant pour les protéines au potentiel immunorégulateur ont été synthétisés et injectés aux souris conjointement à l’AAV-Ova. Cette stratégie d’immunorégulation vectorisée (VIR) nous a permis d’évaluer la capacité de chacune des protéines à moduler les réponses immunitaires dirigées contre l’Ova directement in vivo. Au total, ce travail a permis de mettre en évidence i) l’intérêt et les limites de la stratégie VIR, ii) celui du rôle délétère de CTLA-4/Fc au long terme sur les lymphocytes Tregs CD4+FoxP3+, périphériques et centraux, iii) et de démontrer l’intérêt de 2 nouvelles molécules dérivées PD-L1/Fc sur la persistance de l’Ova.

Gene therapy consist into introducing genetic material into cells to treat genetic disorders. Most gene therapies use viral vectors to carry the gene within target cells. In case of monogenic disorders, adeno-associated viruses (AAV) has become a vector of choice because of its lack of pathogenicity, its large tropism and its capacity to transduce quiescent cells. The use of AAV is approved in Europe to…

Advisors/Committee Members: Adriouch, Sahil (thesis director).

Subjects/Keywords: Thérapie génique; Point de contrôle immunologique; Tolérance immunitaire; CTLA-4; PD-L1; Vecteur adéno-associé; Vectorisation; Gene Therapy; Immune checkpoint; Immune tolerance; CTLA-4; PD-L1; Adeno-associated vector; Vectorization; 615.8; 616.079

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Dupaty, L. (2018). Evaluation in vivo de protéines immunorégulatrices dérivées de CTLA-4 et de PD-L1 pour leur capacité à inhiber les réponses immunitaires dans le contexte de la thérapie génique musculaire par AAV : In-vivo evaluation of immunoregulatory proteins derived from CTLA-4 and PD-L1 for their capacity to inhibit immuno responses in a context of AAV muscle gene therapy. (Doctoral Dissertation). Normandie. Retrieved from http://www.theses.fr/2018NORMR133

Chicago Manual of Style (16^th Edition):

Dupaty, Léa. “Evaluation in vivo de protéines immunorégulatrices dérivées de CTLA-4 et de PD-L1 pour leur capacité à inhiber les réponses immunitaires dans le contexte de la thérapie génique musculaire par AAV : In-vivo evaluation of immunoregulatory proteins derived from CTLA-4 and PD-L1 for their capacity to inhibit immuno responses in a context of AAV muscle gene therapy.” 2018. Doctoral Dissertation, Normandie. Accessed January 17, 2021. http://www.theses.fr/2018NORMR133.

MLA Handbook (7^th Edition):

Dupaty, Léa. “Evaluation in vivo de protéines immunorégulatrices dérivées de CTLA-4 et de PD-L1 pour leur capacité à inhiber les réponses immunitaires dans le contexte de la thérapie génique musculaire par AAV : In-vivo evaluation of immunoregulatory proteins derived from CTLA-4 and PD-L1 for their capacity to inhibit immuno responses in a context of AAV muscle gene therapy.” 2018. Web. 17 Jan 2021.

Vancouver:

Dupaty L. Evaluation in vivo de protéines immunorégulatrices dérivées de CTLA-4 et de PD-L1 pour leur capacité à inhiber les réponses immunitaires dans le contexte de la thérapie génique musculaire par AAV : In-vivo evaluation of immunoregulatory proteins derived from CTLA-4 and PD-L1 for their capacity to inhibit immuno responses in a context of AAV muscle gene therapy. [Internet] [Doctoral dissertation]. Normandie; 2018. [cited 2021 Jan 17]. Available from: http://www.theses.fr/2018NORMR133.

Council of Science Editors:

Dupaty L. Evaluation in vivo de protéines immunorégulatrices dérivées de CTLA-4 et de PD-L1 pour leur capacité à inhiber les réponses immunitaires dans le contexte de la thérapie génique musculaire par AAV : In-vivo evaluation of immunoregulatory proteins derived from CTLA-4 and PD-L1 for their capacity to inhibit immuno responses in a context of AAV muscle gene therapy. [Doctoral Dissertation]. Normandie; 2018. Available from: http://www.theses.fr/2018NORMR133

Texas Medical Center

22. Roh, Whijae. INTEGRATIVE CANCER IMMUNOGENOMIC ANALYSIS OF SERIAL MELANOMA BIOPSIES REVEALS CORRELATES OF RESPONSE AND RESISTANCE TO SEQUENTIAL CTLA-4 AND PD-1 BLOCKADE TREATMENT.

Degree: PhD, 2017, Texas Medical Center

URL: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/813

► Melanoma is the most malignant form of skin cancer. The five-year survival rate for metastatic melanoma is 19.9%. Although targeted therapy of BRAF and… (more)

▼ Melanoma is the most malignant form of skin cancer. The five-year survival rate for metastatic melanoma is 19.9%. Although targeted therapy of BRAF and MEK inhibitors were developed for melanoma, resistance to therapy is inevitable. Immune checkpoint blockade, which reverses the suppression of the immune system, on the other hand, has shown a durable response in 20-30% of patients with metastatic melanoma. However, more predictive and robust biomarkers of response to this therapy are still needed, and resistance mechanisms remain incompletely understood. To address this, we examined a cohort of metastatic melanoma patients treated with sequential checkpoint blockade against cytotoxic T lymphocyte antigen–4 (CTLA-4) followed by programmed death receptor–1 (PD-1) by immunogenomic profile analyses from serial tumor biopsies. From immune profiling (12 marker immunohistochemistry and NanoString Gene Expression Profiling), we found that adaptive immune signatures in tumor biopsies obtained from early on-treatment time points are predictive of response to immune checkpoint blockade. We also demonstrated differential mechanistic signatures of tumor microenvironment induced by CTLA-4 and PD-1 blockade. Importantly, VEGFA was identified as a potential target of combination therapy withPD-1blockade. From genomic profiling (whole exome sequencing and T cell receptor sequencing), we demonstrated that a higher TCR clonality in pre-treatment biopsy was predictive of response to PD-1 but notCTLA-4blockade. We also observed increased TCR clonality after CTLA-4 blockade treatment in patients responding to the following PD-1 blockade treatment. Analysis of copy number alterations (CNAs) identified a higher burden of copy number loss in nonresponders to CTLA-4 and PD-1 blockade and found that it was associated with decreased expression of genes in immune-related pathways. The effect of mutational load and burden of copy number loss on response was nonredundant, suggesting the potential utility of these as a combinatorial biomarker to optimize patient care with checkpoint blockade therapy. In summary, our integrative cancer immunogenomic analysis shows that genomic and immune profiling of longitudinal tumor biopsies can identify novel biomarkers and resistance mechanisms of immune checkpoint blockade. Advisors/Committee Members: P. Andrew Futreal, Ph.D., James P. Allison, Ph.D., Giulio Draetta, M.D., Ph.D..

Subjects/Keywords: cancer immunology; immunotherapy; immune checkpoint blockade; CTLA-4; PD-1; genomics; melanoma; response; resistance; biomarker; Bioinformatics; Computational Biology; Genomics; Medical Immunology; Medicine and Health Sciences; Skin and Connective Tissue Diseases

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Roh, W. (2017). INTEGRATIVE CANCER IMMUNOGENOMIC ANALYSIS OF SERIAL MELANOMA BIOPSIES REVEALS CORRELATES OF RESPONSE AND RESISTANCE TO SEQUENTIAL CTLA-4 AND PD-1 BLOCKADE TREATMENT. (Doctoral Dissertation). Texas Medical Center. Retrieved from https://digitalcommons.library.tmc.edu/utgsbs_dissertations/813

Chicago Manual of Style (16^th Edition):

Roh, Whijae. “INTEGRATIVE CANCER IMMUNOGENOMIC ANALYSIS OF SERIAL MELANOMA BIOPSIES REVEALS CORRELATES OF RESPONSE AND RESISTANCE TO SEQUENTIAL CTLA-4 AND PD-1 BLOCKADE TREATMENT.” 2017. Doctoral Dissertation, Texas Medical Center. Accessed January 17, 2021. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/813.

MLA Handbook (7^th Edition):

Roh, Whijae. “INTEGRATIVE CANCER IMMUNOGENOMIC ANALYSIS OF SERIAL MELANOMA BIOPSIES REVEALS CORRELATES OF RESPONSE AND RESISTANCE TO SEQUENTIAL CTLA-4 AND PD-1 BLOCKADE TREATMENT.” 2017. Web. 17 Jan 2021.

Vancouver:

Roh W. INTEGRATIVE CANCER IMMUNOGENOMIC ANALYSIS OF SERIAL MELANOMA BIOPSIES REVEALS CORRELATES OF RESPONSE AND RESISTANCE TO SEQUENTIAL CTLA-4 AND PD-1 BLOCKADE TREATMENT. [Internet] [Doctoral dissertation]. Texas Medical Center; 2017. [cited 2021 Jan 17]. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/813.

Council of Science Editors:

Roh W. INTEGRATIVE CANCER IMMUNOGENOMIC ANALYSIS OF SERIAL MELANOMA BIOPSIES REVEALS CORRELATES OF RESPONSE AND RESISTANCE TO SEQUENTIAL CTLA-4 AND PD-1 BLOCKADE TREATMENT. [Doctoral Dissertation]. Texas Medical Center; 2017. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/813

University of Debrecen

23. Ben Simon, Avner Israel. Recent developments in immunotherapy of malignant melanoma .

Degree: DE – Általános Orvostudományi Kar, University of Debrecen

URL: http://hdl.handle.net/2437/257243

Recent advances in research and treatments for malignant melanoma. genetically targeted therapy, immune modulating therapy including Checkpoint Inhibitors, Signal-Transduction Inhibitors and their effect on the course of the disease. Advisors/Committee Members: Megyeri, Attila (advisor), Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet (advisor).

Subjects/Keywords: immunotherapy; melanoma; Checkpoint Inhibitors; Anti–PD; Anti–CTLA-4; BRAF Inhibitors; PD-L1

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Ben Simon, A. I. (n.d.). Recent developments in immunotherapy of malignant melanoma . (Thesis). University of Debrecen. Retrieved from http://hdl.handle.net/2437/257243

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Ben Simon, Avner Israel. “Recent developments in immunotherapy of malignant melanoma .” Thesis, University of Debrecen. Accessed January 17, 2021. http://hdl.handle.net/2437/257243.

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Ben Simon, Avner Israel. “Recent developments in immunotherapy of malignant melanoma .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Ben Simon AI. Recent developments in immunotherapy of malignant melanoma . [Internet] [Thesis]. University of Debrecen; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/2437/257243.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

Council of Science Editors:

Ben Simon AI. Recent developments in immunotherapy of malignant melanoma . [Thesis]. University of Debrecen; Available from: http://hdl.handle.net/2437/257243

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

University of Debrecen

24. Najar, Diar Karim. Recent results with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer .

Degree: DE – Általános Orvostudományi Kar, University of Debrecen

URL: http://hdl.handle.net/2437/280310

► I have done my thesis about Recent results with immune checkpoint inhibitors in advanced stage non small cell lung cancer. In my thesis I discuss… (more)

Subjects/Keywords: Thesis; Immun-oncotherapy; PD-1L Inhibitors; CTLA-4 Blockers; Pharmacology; PD-1 Inhibitors

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Najar, D. K. (n.d.). Recent results with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer . (Thesis). University of Debrecen. Retrieved from http://hdl.handle.net/2437/280310

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Najar, Diar Karim. “Recent results with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer .” Thesis, University of Debrecen. Accessed January 17, 2021. http://hdl.handle.net/2437/280310.

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Najar, Diar Karim. “Recent results with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Najar DK. Recent results with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer . [Internet] [Thesis]. University of Debrecen; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/2437/280310.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

Council of Science Editors:

Najar DK. Recent results with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer . [Thesis]. University of Debrecen; Available from: http://hdl.handle.net/2437/280310

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

25. Πεκτασίδη, Ειρήνη. Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με κακόηθες μελάνωμα.

Degree: 2009, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)

URL: http://hdl.handle.net/10442/hedi/29732

►

Purpose: Interferon is approved for adjuvant treatment of patients with stage llb/lll melanoma. The toxicity and uncertainty regarding survival benefits of interferon have qualified its… (more)

▼

Purpose: Interferon is approved for adjuvant treatment of patients with stage llb/lll melanoma. The toxicity and uncertainty regarding survival benefits of interferon have qualified its acceptance, despite significant durable relapse prevention in a fraction of patients. Predictive biomarkers that would enable selection of patients for therapy would have a large impact upon clinical practice. Specific CTLA-4 polymorphisms have previously shown an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of autoimmunity. Experimental design: 286 melanoma patients and 288 healthy controls were genotyped for six CTLA-4 polymorphisms previously suggested to be important (AG 49, CT 318, CT 60, JO 27, JO 30 and JO 31). Specific allele frequencies were compared between the healthy and patient populations, as well as presence or absence of these in relation to recurrence. Alleles related to autoimmune disease were also investigated. Results: No significant differences were found between the distributions of CTLA-4 polymorphisms in the melanoma population compared with healthy controls. Relapse free survival (RFS) and overall survival (OS) did not differ significantly between patients with the alleles represented by these polymorphisms. No correlation between autoimmunity and specific alleles was shown. The six polymorphisms evaluated where strongly associated (Fisher’s exact p-values<0.001 for all associations) and significant linkage disequilibrium among these was indicated. Conclusion: No polymorphisms of CTLA-4 defined by the SNPs studied were correlated with improved RFS, OS, or autoimmunity in this high-risk group of melanoma patients.

Σκοπός: Η ιντερφερόνη θεωρείται καθιερωμένη επικουρική θεραπεία σε ασθενείς με κακοήθες μελάνωμα σταδίων IIB, IIC και III. Είναι όμως περιορισμένης αποδοχής λόγω της τοξικότητας και της αβεβαιότητας όσον αφορά το όφελος της επιβίωσης, καίτοι βελτιώνει σημαντικά την ελεύθερη υποτροπής επιβίωση σε μία υποομάδα ασθενών με κακοήθες μελάνωμα. Επομένως, θα ήταν χρήσιμο να κατανοήσουμε καλύτερα τους μηχανισμούς δράσης της ιντερφερόνης άλφα-2b και να αναγνωρίσουμε προγνωστικούς δείκτες που θα μας επιτρέψουν να ξεχωρίσουμε τους ασθενείς που είναι πιθανότερο να ωφεληθούν από τη θεραπεία με IFN-a2b. Ο σκοπός αυτής της μελέτης είναι η αναζήτηση 6 πολυμορφισμών του CTLA-4 και η εκτίμηση της επίδρασης της έκφρασής τους στην επιβίωση ασθενών με μελάνωμα υψηλού κινδύνου οι οποίοι λαμβάνουν επικουρική θεραπεία με ιντερφερόνη υψηλής δόσης (HDI). Μεθοδολογία και ασθενείς: Στη μελέτη περιλήφθηκαν διακόσιοι ογδόντα τέσσερις (284) ασθενείς με μελάνωμα σταδίου IIB, IIC και III και 246 υγιείς μάρτυρες. Περιφερικό αίμα ελήφθη πριν από την έναρξη της επικουρικής ανοσοθεραπείας με ιντερφερόνη. To DNA απομονώθηκε χρησιμοποιώντας το σύστημα εξαγωγής GenoPrep και για την ανίχνευση των πολυμορφισμών (SNP-PCR) του CTLA-4 (AG 49, CT 60, CT 318, JO 27, JO 30, JO 31 και του HLA-Cw*06) χρησιμοποιήθηκε η αλυσιδωτή αντίδραση της πολυμεράσης. Όλες οι αντιδράσεις ανάγνωσης…

Subjects/Keywords: Μελάνωμα; Πολυμορφισμός; Επικουρική θεραπεία; Ιντερφερόνη; Melanoma; Polymorphisms; CTLA-4; Adjuvant therapy; Interferon

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Πεκτασίδη, . �. (2009). Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με κακόηθες μελάνωμα. (Thesis). National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Retrieved from http://hdl.handle.net/10442/hedi/29732

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Πεκτασίδη, Ειρήνη. “Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με κακόηθες μελάνωμα.” 2009. Thesis, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Accessed January 17, 2021. http://hdl.handle.net/10442/hedi/29732.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Πεκτασίδη, Ειρήνη. “Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με κακόηθες μελάνωμα.” 2009. Web. 17 Jan 2021.

Vancouver:

Πεκτασίδη �. Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με κακόηθες μελάνωμα. [Internet] [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2009. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10442/hedi/29732.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Πεκτασίδη �. Μελέτη των πολυμορφισμών του γονιδίου CTLA-4 σε ασθενείς με κακόηθες μελάνωμα. [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2009. Available from: http://hdl.handle.net/10442/hedi/29732

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

26. Anderson, Kathleen. CD25+ CTLA-4+ T Cell-Dependent Induction of Anergic CD25- T Cells Limits the Immune Response to H. pylori Infection Resulting in Mild Gastritis and Persistent Colonization.

Degree: PhD, Pathology, 2006, Case Western Reserve University School of Graduate Studies

URL: http://rave.ohiolink.edu/etdc/view?acc_num=case1144332338

► Helicobacter pylori (H. pylori) is a gastric pathogen infecting more than half the world’s population. H. pylori infection induces gastric inflammation but the host fails… (more)

▼ Helicobacter pylori (H. pylori) is a gastric pathogen infecting more than half the world’s population. H. pylori infection induces gastric inflammation but the host fails to generate protective immunity. It has been established that infection lasts for the life of the host despite the induction of inflammation and adaptive immune responses. It has also previously demonstrated that protective immunity is CD4+ T cell-dependent while CD4+ T cells remain hyporesponsive during chronic infection. Therefore, we evaluated the immunologic mechanisms that contribute to the failure of the CD4+ T cells to promote active immunity to H. pylori in the murine model of H. pylori infection. We demonstrate here that the H. pylori-specific T cells are predominantly anergic. We provide in vitro and in vivo evidence that while CD25+ regulatory T cells are required to induce this anergic state in bystander CD25- cells, the CD25- T cells remain hyporesponsive even when the regulatory T cells have been removed. Interestingly, even CD25- cells that arise in the absence of regulatory T cells and therefore are capable of promoting eradication of H. pylori can be down-regulated when combined with regulatory T cells. These results demonstrate that CD25+ regulatory T cells not only influence naïve CD25- cells but may also limit the response of previously-activated CD25- cells. Finally, we address the mechanism by which the anergic state is induced by showing that CTLA-4 engagement on the surface of CD25+ regulatory T cells plays a critical role in the H. pylori immune response. These findings demonstrating functional inactivation are in accord with the success of therapeutic immunization in which protective immunity is permitted to develop in the face of active chronic inflammation resulting from initial infection. Based on data presented in this thesis, we hypothesize that CTLA-4 expression by CD25+ regulatory T cells induces anergy in bystander CD25- responder cells resulting in a reduced immune response and persistent infection. Advisors/Committee Members: Blanchard, Thomas (Advisor).

Subjects/Keywords: Health Sciences, Immunology; H. pylori; anergy; regulatory T cells; CTLA-4

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Anderson, K. (2006). CD25+ CTLA-4+ T Cell-Dependent Induction of Anergic CD25- T Cells Limits the Immune Response to H. pylori Infection Resulting in Mild Gastritis and Persistent Colonization. (Doctoral Dissertation). Case Western Reserve University School of Graduate Studies. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=case1144332338

Chicago Manual of Style (16^th Edition):

Anderson, Kathleen. “CD25+ CTLA-4+ T Cell-Dependent Induction of Anergic CD25- T Cells Limits the Immune Response to H. pylori Infection Resulting in Mild Gastritis and Persistent Colonization.” 2006. Doctoral Dissertation, Case Western Reserve University School of Graduate Studies. Accessed January 17, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=case1144332338.

MLA Handbook (7^th Edition):

Anderson, Kathleen. “CD25+ CTLA-4+ T Cell-Dependent Induction of Anergic CD25- T Cells Limits the Immune Response to H. pylori Infection Resulting in Mild Gastritis and Persistent Colonization.” 2006. Web. 17 Jan 2021.

Vancouver:

Anderson K. CD25+ CTLA-4+ T Cell-Dependent Induction of Anergic CD25- T Cells Limits the Immune Response to H. pylori Infection Resulting in Mild Gastritis and Persistent Colonization. [Internet] [Doctoral dissertation]. Case Western Reserve University School of Graduate Studies; 2006. [cited 2021 Jan 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=case1144332338.

Council of Science Editors:

Anderson K. CD25+ CTLA-4+ T Cell-Dependent Induction of Anergic CD25- T Cells Limits the Immune Response to H. pylori Infection Resulting in Mild Gastritis and Persistent Colonization. [Doctoral Dissertation]. Case Western Reserve University School of Graduate Studies; 2006. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=case1144332338

27. Lévy, Eva. Identification de causes génétiques du syndrome d’Evans pédiatrique : Identifying genetic causes of pediatric Evans syndrome.

Degree: Docteur es, Immunologie, 2016, Sorbonne Paris Cité

URL: http://www.theses.fr/2016USPCB017

► Le syndrome d'Evans est défini par l'existence concomitante ou séquentielle de cytopénies auto-immunes, le plus souvent, anémie hémolytique et thrombopénie immunologique. Chez l'enfant, il peut… (more)

▼ Le syndrome d'Evans est défini par l'existence concomitante ou séquentielle de cytopénies auto-immunes, le plus souvent, anémie hémolytique et thrombopénie immunologique. Chez l'enfant, il peut être secondaire à une infection, une maladie auto-immune systémique ou un déficit immunitaire primitif. Alternativement, chez une grande partie des patients, l'étiologie n'est pas clairement identifiée. Les patients atteints de syndrome d'Evans présentent parfois d'autres atteintes, telles une auto-immunité d'organe, une lymphoprolifération bénigne ou un déficit immunitaire. L'objectif de ce travail était d'identifier des causes génétiques chez des enfants présentant un syndrome d'Evans sans étiologie sous-jacente identifiée. Nous avons centré notre étude sur des formes sévères à début pédiatrique en faisant l'hypothèse qu'une maladie monogénique serait plus fréquente dans ce groupe de patients. Nous avons mis à profit les technologies de séquençage haut débit « nouvelle génération » (NGS) pour réaliser et analyser le séquençage de l'exome de patients et de certains de leurs apparentés afin de mettre en évidence des gènes candidats potentiels. Ce travail a permis l'identification de 4 gènes candidats : LRBA, CTLA-4, STAT3 (mutations gain de fonction) et NFKBIA. L'implication des 3 premiers gènes dans de nouvelles maladies monogéniques où l'auto-immunité est au premier plan a été confirmée par d'autres équipes au cours de ce travail. Pour chacun de ces gènes, nous avons poursuivi 2 objectifs complémentaires : d'une part, tenter de valider l'implication des gènes identifiés dans la maladie des patients. Nous avons pour cela utilisé des approches et techniques variées : biochimie et protéomique afin d'identifier des partenaires protéiques, microscopie confocale pour localiser les protéines et leurs interactions, tests cellulaires in vitro pour mettre en évidence un défaut fonctionnel, marquages en cytométrie en flux pour identifier des modifications dans les sous-populations lymphocytaires. D'autre part, nous avons recherché d'autres mutations de ces gènes chez des patients de phénotype clinique similaire. Nous avons ainsi constitué et exploré 3 cohortes de patients présentant des mutations de LRBA, CTLA-4 ou STAT3. Nous avons rassemblé une cohorte de 18 patients porteurs d'une mutation de LRBA, répartis dans 11 familles. Cela nous a permis de préciser et d'étendre le spectre clinique de cette maladie de découverte récente, avec en particulier des atteintes articulaires sévères s'associant à un diabète précoce, ou des entéropathies. Nous avons identifié 15 nouvelles mutations de transmission autosomique récessive dans le gène LRBA, codant une protéine de fonction inconnue dont l'absence entraine une maladie principalement caractérisée par une poly-auto-immunité. Nous avons identifié 29 partenaires protéiques potentiels de LRBA et précisé la localisation de LRBA dans les différents compartiments cellulaires. Nous avons également établi une cohorte de 12 patients dans 10 familles présentant un déficit en CTLA-4 par… Advisors/Committee Members: Quartier, Pierre (thesis director).

Subjects/Keywords: Syndrome d'Evans; Anémie hémolytique auto-immune; Purpura thrombopénique immunologique; Auto-immunité; Maladie génétique; Séquençage de l'exome; LRBA; CTLA-4; STAT3 gain de fonction; Lymphocytes T régulateurs; Pédiatrie; Déficit immunitaire; Evans syndrome; Autoimmune hemolytic anemia; Immune thrombocytopenia; Autoimmunity; Genetic disease; Exome sequencing; LRBA; CTLA-4; STAT3 gain-of-function; Regulatory T lymphocytes; Pediatrics; Immune deficiency; 571.96

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Lévy, E. (2016). Identification de causes génétiques du syndrome d’Evans pédiatrique : Identifying genetic causes of pediatric Evans syndrome. (Doctoral Dissertation). Sorbonne Paris Cité. Retrieved from http://www.theses.fr/2016USPCB017

Chicago Manual of Style (16^th Edition):

Lévy, Eva. “Identification de causes génétiques du syndrome d’Evans pédiatrique : Identifying genetic causes of pediatric Evans syndrome.” 2016. Doctoral Dissertation, Sorbonne Paris Cité. Accessed January 17, 2021. http://www.theses.fr/2016USPCB017.

MLA Handbook (7^th Edition):

Lévy, Eva. “Identification de causes génétiques du syndrome d’Evans pédiatrique : Identifying genetic causes of pediatric Evans syndrome.” 2016. Web. 17 Jan 2021.

Vancouver:

Lévy E. Identification de causes génétiques du syndrome d’Evans pédiatrique : Identifying genetic causes of pediatric Evans syndrome. [Internet] [Doctoral dissertation]. Sorbonne Paris Cité; 2016. [cited 2021 Jan 17]. Available from: http://www.theses.fr/2016USPCB017.

Council of Science Editors:

Lévy E. Identification de causes génétiques du syndrome d’Evans pédiatrique : Identifying genetic causes of pediatric Evans syndrome. [Doctoral Dissertation]. Sorbonne Paris Cité; 2016. Available from: http://www.theses.fr/2016USPCB017

Texas Medical Center

28. Jaiswal, Ashvin. TUMOR IMMUNOTHERAPY: MECHANISMS OF ACQUIRED RESISTANCE AND CHARACTERIZATION OF IMMUNE RELATED TOXICITIES.

Degree: PhD, 2018, Texas Medical Center

URL: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/832

► Tumor immunotherapy has shown very promising clinical benefit across an array of cancers; however, two major challenges remain unresolved in the field. First, many… (more)

▼ Tumor immunotherapy has shown very promising clinical benefit across an array of cancers; however, two major challenges remain unresolved in the field. First, many patients do not respond to therapy at all or relapse after a period of remission. Second, there are often dose-limiting immune related adverse effects associated with immunomodulation. In order to understand the mechanisms employed by tumors to evade immunotherapeutic responses, we established a murine model of melanoma designed to elucidate the molecular mechanisms underlying immunotherapy resistance. Through multiple in vivo passages, we selected a B16 melanoma tumor line that evolved complete resistance to combination blockade of CTLA-4, PD-1, and PD-L1, which cures ~80% of mice bearing the parental tumor. Using gene expression analysis, and immunogenomics, we determined the adaptations engaged by this melanoma to become completely resistant to triple combination T cell checkpoint blockade. Acquisition of immunotherapy resistance by these melanomas was driven by the coordinated upregulation of the glycolytic, oxidoreductase, and mitochondrial oxidative phosphorylation pathways to create a metabolically hostile microenvironment wherein T cell functions are suppressed. Together these data indicate that by adapting a hyper-metabolic phenotype, melanoma tumors can achieve resistance to T cell checkpoint blockade allowing them to escape host immune control. Increasing the potency of antitumor immunity with immunotherapy disrupts the tightly controlled state of immunologic homeostasis in the body which can lead to reactivation of peripherally-tolerized T cell responses with the potential to mediate uninvited toxicities. Agonist antibodies targeting the T cell co-stimulatory receptor 4-1BB (CD137) are among the most effective immunotherapeutic agents across pre-clinical cancer models. Clinical development of these agents, however, has been hampered by dose-limiting liver toxicity. Lack of knowledge of the mechanisms underlying this toxicity has limited the potential to separate 4-1BB agonist driven tumor immunity from hepatotoxicity. The capacity of 4-1BB agonist antibodies to induce liver toxicity was investigated in wild type and genetically-modified immunocompetent mice. We find that activation of 4-1BB on liver myeloid cells is essential to initiate hepatitis. Once activated, these cells produce interleukin-27 that is required for liver toxicity. CD8 T cells infiltrate the liver in response to this myeloid activation and mediate tissue damage. Co-administration of CTLA-4 and/or CCR2 blockade may minimize hepatitis, but yield equal or greater antitumor immunity. Advisors/Committee Members: Dr. Michael A. Curran, Ph.D., Dr. James P. Allison, Ph.D., Dr. Willem Overwijk, Ph.D..

Subjects/Keywords: Immunotherapy Resistance; Immunooncology; CTLA-4; PD-1; PD-L1; 4-1BB; Immune Related Adverse Effects (IRAEs); Immunometabolism; Checkpoint Blockade Immunotherapy; Hepatotoxicity; Genetic Processes; Immunity; Immunology and Infectious Disease; Immunopathology; Immunoprophylaxis and Therapy; Medical Biochemistry; Medical Biotechnology; Medical Genetics; Medical Immunology; Medicine and Health Sciences

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Jaiswal, A. (2018). TUMOR IMMUNOTHERAPY: MECHANISMS OF ACQUIRED RESISTANCE AND CHARACTERIZATION OF IMMUNE RELATED TOXICITIES. (Doctoral Dissertation). Texas Medical Center. Retrieved from https://digitalcommons.library.tmc.edu/utgsbs_dissertations/832

Chicago Manual of Style (16^th Edition):

Jaiswal, Ashvin. “TUMOR IMMUNOTHERAPY: MECHANISMS OF ACQUIRED RESISTANCE AND CHARACTERIZATION OF IMMUNE RELATED TOXICITIES.” 2018. Doctoral Dissertation, Texas Medical Center. Accessed January 17, 2021. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/832.

MLA Handbook (7^th Edition):

Jaiswal, Ashvin. “TUMOR IMMUNOTHERAPY: MECHANISMS OF ACQUIRED RESISTANCE AND CHARACTERIZATION OF IMMUNE RELATED TOXICITIES.” 2018. Web. 17 Jan 2021.

Vancouver:

Jaiswal A. TUMOR IMMUNOTHERAPY: MECHANISMS OF ACQUIRED RESISTANCE AND CHARACTERIZATION OF IMMUNE RELATED TOXICITIES. [Internet] [Doctoral dissertation]. Texas Medical Center; 2018. [cited 2021 Jan 17]. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/832.

Council of Science Editors:

Jaiswal A. TUMOR IMMUNOTHERAPY: MECHANISMS OF ACQUIRED RESISTANCE AND CHARACTERIZATION OF IMMUNE RELATED TOXICITIES. [Doctoral Dissertation]. Texas Medical Center; 2018. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/832

Université de Montréal

29. Bastien, Jean-Philippe. Traitement de la maladie du greffon contre l’hôte chronique par la photophérèse extra corporelle au TH9402 : m écanisme de régulation de la maladie du greffon contre l’hôte chronique par les cellules T régulatrices.

Degree: 2016, Université de Montréal

URL: http://hdl.handle.net/1866/15983

Subjects/Keywords: GVHD chronique; TH9402; Cellule T régulatrice; CTLA-4; IDO; GCN2; Cellules dendritiques; Chronic GVHD; TH9402; Regulatory T cells; CTLA-4; IDO; GCN2; Dendritic cells; Health Sciences - Immunology / Sciences de la santé - Immunologie (UMI : 0982)

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Bastien, J. (2016). Traitement de la maladie du greffon contre l’hôte chronique par la photophérèse extra corporelle au TH9402 : m écanisme de régulation de la maladie du greffon contre l’hôte chronique par les cellules T régulatrices. (Thesis). Université de Montréal. Retrieved from http://hdl.handle.net/1866/15983

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Bastien, Jean-Philippe. “Traitement de la maladie du greffon contre l’hôte chronique par la photophérèse extra corporelle au TH9402 : m écanisme de régulation de la maladie du greffon contre l’hôte chronique par les cellules T régulatrices.” 2016. Thesis, Université de Montréal. Accessed January 17, 2021. http://hdl.handle.net/1866/15983.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Bastien, Jean-Philippe. “Traitement de la maladie du greffon contre l’hôte chronique par la photophérèse extra corporelle au TH9402 : m écanisme de régulation de la maladie du greffon contre l’hôte chronique par les cellules T régulatrices.” 2016. Web. 17 Jan 2021.

Vancouver:

Bastien J. Traitement de la maladie du greffon contre l’hôte chronique par la photophérèse extra corporelle au TH9402 : m écanisme de régulation de la maladie du greffon contre l’hôte chronique par les cellules T régulatrices. [Internet] [Thesis]. Université de Montréal; 2016. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/1866/15983.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Bastien J. Traitement de la maladie du greffon contre l’hôte chronique par la photophérèse extra corporelle au TH9402 : m écanisme de régulation de la maladie du greffon contre l’hôte chronique par les cellules T régulatrices. [Thesis]. Université de Montréal; 2016. Available from: http://hdl.handle.net/1866/15983

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Queensland

30. Harjunpaa, Heidi Margareta. Tumor immunity and autoimmunity following cancer immunotherapy.

Degree: School of Medicine, 2019, University of Queensland

URL: http://espace.library.uq.edu.au/view/UQ:6

Subjects/Keywords: Cancer; Immunotherapy; IrAEs; Immune checkpoint receptor; CTLA-4; PD-1; CD96; TIGIT; Multiple myeloma; 1107 Immunology; 1112 Oncology and Carcinogenesis

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Harjunpaa, H. M. (2019). Tumor immunity and autoimmunity following cancer immunotherapy. (Thesis). University of Queensland. Retrieved from http://espace.library.uq.edu.au/view/UQ:6

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Harjunpaa, Heidi Margareta. “Tumor immunity and autoimmunity following cancer immunotherapy.” 2019. Thesis, University of Queensland. Accessed January 17, 2021. http://espace.library.uq.edu.au/view/UQ:6.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Harjunpaa, Heidi Margareta. “Tumor immunity and autoimmunity following cancer immunotherapy.” 2019. Web. 17 Jan 2021.

Vancouver:

Harjunpaa HM. Tumor immunity and autoimmunity following cancer immunotherapy. [Internet] [Thesis]. University of Queensland; 2019. [cited 2021 Jan 17]. Available from: http://espace.library.uq.edu.au/view/UQ:6.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Harjunpaa HM. Tumor immunity and autoimmunity following cancer immunotherapy. [Thesis]. University of Queensland; 2019. Available from: http://espace.library.uq.edu.au/view/UQ:6

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

		in
And / Or
		in
And / Or
		in
And / Or
		in

Open Access Theses and Dissertations